Stockwinners Market Radar for June 25, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:00 EDT MSC Industrial acquires ApTex and Premier Tool Grinding - MSC Industrial "announced that it has acquired ApTex, Inc. and Premier Tool Grinding, Inc. Under the purchase agreements, both companies will continue to operate under their current names as MSC companies. Combined, the two companies had estimated revenues of slightly over $20 million in 2023 and have 58 associates. Both acquisitions are expected to be net neutral to MSC's fiscal year 2024 net income."

18:57 EDT Twelve Seas Investment Company II terminates Crystal Lagoons combination - Twelve Seas Investment Company II announced that its previously announced Agreement and Plan of Merger in connection with its planned business combination with Crystal Lagoons U.S. Corp., a Delaware corporation and CL Newco Inc., a Delaware corporation was terminated by Crystal Lagoons due to the conditions to the closing of the initial business combination not being satisfied or waived by the outside date of May 31, 2024. The Company will not seek an alternative business combination. Additionally, the Company announced today that (i) the amount paid to its public stockholders was $10.64 per public share, rather than the previously reported $10.558 per public share (the "Final Redemption Amount"), (ii) the Company's securities were delisted from the over-the-counter market on June 20, 2024 in connection with the payment of the Final Redemption Amount and (iii) it expects that the Nasdaq Stock Market LLC will file a Form 25 with the U.S. Securities and Exchange Commission on June 28, 2024.

18:21 EDT Seadrill approves initial step of $200M of its share repurchase program - Seadrill announced that it has continued progress on its share repurchase program, as part of its ongoing commitment to deliver shareholder returns. The Company completed the $250M share repurchase program initiated in December 2023 and will cancel the acquired shares. As previously announced, the Company's Board of Directors authorized a new $500M share repurchase program that will run for a period of two years from the completion of the 2023 program. As an initial step under the new repurchase program, the Board has authorized the Company to purchase up to $200M of the Company's common shares by September 30 and the Company has entered an agreement with DNB Markets to effect the First Tranche in open market transactions on the OSE and the NYSE. The Company will commence the First Tranche on June 26, and will complete the First Tranche by September 30; provided, however, that the Company may discontinue or suspend the repurchases under the First Tranche at any time without notice.

18:10 EDT Norfolk Southern 'appreciates' findings of NTSB investigation - Norfolk Southern Corporation issued the following statement regarding the findings of the National Transportation Safety Board on the derailment in East Palestine, Ohio: "Norfolk Southern appreciates the NTSB's investigation, recommendations for enhancing rail safety and the acknowledgement of the steps Norfolk Southern has taken to improve safety. We share the commitment and over the last 16 months have implemented many enhancements and technologies to make our railroad even safer. Among the NTSB recommendations specific to Norfolk Southern, we have taken action to enable the immediate availability of train consist information to first responders and encourage contractors to share information to make emergency response decisions. In addition, we have substantially addressed the Federal Railroad Administration (FRA) recommendations from its 2023 Safety Culture Assessment. As a result of these actions and others, Norfolk Southern's mainline accident rate declined 38% last year to industry leading levels. We will move quickly to compare the NTSB's recommendations to our current protocols and will implement those that advance our safety culture."

17:49 EDT CFIUS clears Vista Outdoor's sale of The Kinetic Group - The company states: "Vista Outdoor and Czechoslovak Group a.s., or CSG, announced that the Committee on Foreign Investment in the United States, or CFIUS, has cleared CSG's proposed acquisition of Vista Outdoor's The Kinetic Group business. Vista Outdoor and CSG received written notice from CFIUS that CFIUS has concluded its review and investigation of the Transaction and has determined that there are no unresolved national security concerns. CFIUS clearance was the final regulatory approval required under the merger agreement with CSG for the closing of the Transaction. The Board continues to recommend Vista Outdoor stockholders vote in favor of the proposal to adopt the merger agreement with CSG. Vista Outdoor is confident that the Transaction will maximize value for our stockholders by: Providing for a $2 billion purchase price, representing a $90 million increase from the original $1.91 billion purchase price, Allowing stockholders to benefit directly from additional excess cash generated by the Company prior to closing; Delivering $18.00 in cash consideration per share at closing, representing a $5.10 increase from the original cash consideration of $12.90 per share; and Enabling stockholders to capture the long-term intrinsic value that is embedded in Revelyst's business plan as a standalone public company."

17:21 EDT FedEx sees demand environment improving in FY25 - Sees LTL volume improving as year progresses.

17:02 EDT Disney World debuts 'Lightning Lane Multi Pass,' for ride reservations - "The days leading up to a Walt Disney World vacation are always so exciting. For many, it's a time when families and friends get the chance to reunite and talk about their must-dos while they're here, including their favorite rides and experiences. We enjoy hearing from guests about all the things they love, as well as how we can make their experience even better the next time. At Walt Disney World, guests have told us they would prefer to have the option to do more of their planning before their theme park day. So, this summer we will make changes to our Disney Genie+ service and individual Lightning Lane entry, including new ways to plan ahead.On July 24, Walt Disney World will introduce new, simpler names to provide more clarity for everyone. Disney Genie+ service will become Lightning Lane Multi Pass, while individual Lightning Lane will now be known as Lightning Lane Single Pass, " said the company in a blog posting. Reference Link

16:58 EDT General Motors announces executive changes - In a regulatory filing, the company states: "On June 24, 2024, the General Motors Company Board of Directors (approved the election of Craig B. Glidden to a new role as the Company's Executive Vice President and Strategic Advisor, a position he will hold through December 31, 2024. He will also remain the President and Chief Administrative Officer of GM Cruise Holdings LLC, the Company's autonomous vehicle technology subsidiary, where he will support Cruise's newly appointed Chief Executive Officer, Marc Whitten. In addition, the Board elected Grant M. Dixton to succeed Mr. Glidden and serve as the Company's Executive Vice President and Chief Legal and Public Policy Officer. The Company's leadership changes will be effective as of July 15, 2024."

16:53 EDT Epsilon Energy announces increased borrowing base, Permian operations update - The company states: "Epsilon Energy reported the results of a borrowing base redetermination on the Company's senior secured reserve-based revolving credit facility with Frost Bank. Effective on June 21, 2024, the Lender redetermined the Company's borrowing base at $45 million, which will remain until the next redetermination in the fourth quarter of 2024. The borrowing base now includes the recently acquired and developed properties in Ector County, Texas. The Lender's total commitment is equal to the borrowing base amount. All other terms of the Credit Facility remain the same. In Ector County, Texas, the recently completed Ava well, the sixth well drilled in the Pradera Fuego project, started flow-back in mid-May. Over the last twenty-five days, the well has averaged 1,290 BOEPD from a ~11,000' lateral. The well is the best performer in the project so far, outperforming pre-drill estimates. Completion operations are now underway on the Katy well, with flow-back expected next month. This well extends into the large undeveloped Cowden leasehold, in which the Company acquired an interest in June 2023. Epsilon holds a 25% working interest in the Pradera Fuego project."

16:32 EDT Cava Group director sells $8.2M in common stock - In a regulatory filing, Cava Group disclosed that its director Theodoros Xenohristos sold 90K shares of common stock on June 24th in a total transaction size of $8.2M.

16:31 EDT Rhinebeck Bancorp appoints Kevin Nihill CFO - Rhinebeck Bancorp, the holding company of Rhinebeck Bank, announced the appointment of Kevin Nihill as CFO of Rhinebeck Bancorp and Rhinebeck Bank. Nihill replaced former CFO Michael McDermott, who retired from the bank after 23 years of service. Nihill most recently served as executive VP, CFO at St. Mary's Bank, a credit union in Manchester, NH.

16:26 EDT FactSet director Abrams sells 2,375 common shares - In a regulatory filing, FactSet director Robin Ann Abrams disclosed the sale of 2,375 common shares of the company on June 25 at a price of $420.71 per share.

20:21 EDT Volkswagen plans to make $5B investment into Rivian, with $1B initial investment - Rivian Automotive (RIVN) and Volkswagen (VWAGY) announced their intention to form an equally controlled and owned joint venture to create next-generation electrical architecture and best-in-class software technology. The partnership is anticipated to accelerate the development of software for Rivian and Volkswagen Group. It is expected to allow both companies to combine their complementary strengths and lower cost per vehicle by increasing scale and speeding up innovation globally. Rivian's proven in-market zonal hardware design and integrated technology platform are expected to serve as the foundation for future SDV development in the JV that will be applied to both companies' vehicles. Rivian plans to contribute its electrical architecture expertise and is expected to license existing intellectual property rights to the joint venture. Both companies aim to launch vehicles benefiting from the technology created within the joint venture in the second half of the decade. In the short term, the joint venture is expected to enable Volkswagen Group to utilize Rivian's existing electrical architecture and software platform. The partnership's ambition is to accelerate Volkswagen Group's SDV plans and transition to a pure zonal architecture. Each company will continue to separately operate their respective vehicle businesses. Underpinned by the vision of the strategic partnership, Volkswagen Group plans to make a $5 billion investment into Rivian. Initially Volkswagen Group will invest $1 billion in Rivian through an unsecured convertible note that will convert into Rivian's common stock subject to certain conditions upon the later of receipt of regulatory approvals and December 1, 2024. Volkswagen Group is expected to invest a further $4B as part of the transaction. There has been significant work done over the past months to validate that Rivian's electrical architecture and software are compatible with Volkswagen Group's vehicles. The parties currently expect the completion of the JV formation in the fourth quarter of 2024. All transactions described in this release are subject to the completion of definitive agreements, the conditions included in those agreements and the receipt of required regulatory approvals. Lazard is serving as lead financial advisor and BDT & MSD Partners is serving as financial advisor to Rivian.

16:17 EDT DocuSign appoints new Chief Revenue and Chief Technology officers - Docusign announced that Paula Hansen will join the company as President and Chief Revenue Officer and Sagnik Nandy will join as Chief Technology Officer on August 5, completing the company's senior leadership team for its next phase of growth. Reporting to Docusign CEO Allan Thygesen, the two new leaders will lead Docusign's sales and partnership functions and its engineering function, respectively, to fully capitalize on the company's recently announced expansion into a new SaaS category: Intelligent Agreement Management. Earlier this year, Docusign unveiled Docusign IAM, an Intelligent Agreement Management platform and suite of applications to lead that category, which rolled out to U.S. customers on May 30. Leveraging the deep experience of these two senior leaders in pioneering new innovation and growth at scale, Docusign IAM will help businesses of all kinds transform agreement data into actionable insights, accelerate contract review cycles, and boost productivity organization-wide. Most recently, Hansen served as President and Chief Revenue Officer at Alteryx, where she was responsible for leading the global go-to-market organization, which includes worldwide sales, sales engineering, partners, marketing, customer experience, customer support and revenue operations. Most recently, Nandy served as President and Chief Development Officer at Okta, where he led product, engineering and design for the Workforce Identity Cloud, which includes their core identity and access management platform. Earlier, he served as a VP of Engineering at Google. At Docusign, Nandy will partner closely with Dmitri Krakovsky, Chief Product Officer, who leads product management and design.

20:16 EDT KKR acquires $2.1B multifamily portfolio from Quarterra - KKR (KKR) announced that KKR has acquired a portfolio of 18 multifamily assets from a closed-ended fund sponsored by Quarterra Multifamily (LEN), a multifamily real estate development and operating company, for approximately $2.1B. The recently-built, Class A portfolio consists of over 5,200 units concentrated primarily in growing coastal and sunbelt markets including California, Washington, Florida, Texas, Georgia and North Carolina, Colorado and New Jersey. The portfolio is a mix of mid-rise and high-rise buildings featuring convenient access to urban, metropolitan areas, high-quality construction, modern amenities and excellent energy, water and waste efficiency. "We are pleased to acquire this exceptional, well-located multifamily portfolio from one of the world's premier developers and owners of residential real estate," said Justin Pattner, Partner at KKR and Head of Real Estate Equity in the Americas. "We believe this is a great moment to invest in real estate, as transaction activity starts to pick up on the heels of two-years of dislocation in commercial real estate markets. Across our platform we are finding opportunities where our scale, strong relationships, multiple pools of capital and local knowledge give us advantages as a buyer of large pools of high-quality, irreplaceable assets."

16:10 EDT Methode Electronics appoints Jon DeGaynor as president and CEO - Methode Electronics announced that Jon DeGaynor has been appointed President, Chief Executive Officer CEO and a member of the Board of Directors, effective July 15. Mr. DeGaynor succeeds Kevin Nystrom, a partner and managing director at AlixPartners LLP, who has served as interim CEO since May 7. With a 35-year career in engineered-products businesses, Mr. DeGaynor brings to Methode diverse experience at the intersection of operations, technology and strategy. From 2015 to 2023, he served as President and CEO of Stoneridge...

16:08 EDT Tecnoglass to review strategic alternatives, reaffirms FY24 outlook - Tecnoglass announced that its board is conducting a review of the company's strategic alternatives with the assistance of outside financial and legal advisors. The board is committed to acting in the best interests of the company. There is no deadline or definitive timetable set for completion of the strategic alternatives review process and there can be no assurance that this process will result in the company pursuing a transaction or any other particular outcome. The company does not intend to make any further public comment regarding its review of strategic alternatives until the board has approved a specific course of action or the company determines that additional disclosure is appropriate or necessary. Additionally, the company is reaffirming its financial outlook for FY24 provided on May 9.

20:07 EDT Volkswagen to invest $1B in Rivian, to establish joint venture - The Management Board of Volkswagen AG Volkswagen AG (VWAGY) resolved with the approval of the Supervisory Board of Volkswagen AG that Volkswagen will enter into a Convertible Promissory Note Purchase Agreement with Rivian Automotive (RIVN). Under the terms of this agreement, Volkswagen will grant Rivian Automotive a convertible note in the amount of $1B. The note will convert into a direct shareholding of Volkswagen in Rivian Automotive, Inc., upon the receipt of the necessary regulatory approvals, but not before 1 December 2024. The size of the shareholding is determined in accordance with certain average share prices of the shares of Rivian Automotive, Inc., for one half of the equity interest as of the time of the conclusion of the Convertible Promissory Note Purchase Agreement and for the other half of the equity interest as of the conversion day. In addition, Volkswagen and Rivian Automotive intend to establish a joint venture for the purpose of the joint creation of next generation electrical/electronic architecture, or so-called E/E-architecture, for electric vehicles. Volkswagen and Rivian shall each hold a 50% stake in the joint venture, and it shall be equally controlled. Upon successful implementation of the joint venture, Volkswagen would receive immediate access to Rivian Automotive's current E/E-architecture technology for using it in its electric vehicles. The actual establishment of the joint venture depends on a series of different parameters, in particular, the final results of the further review of the technical feasibility of the integration of the E/E-architecture in vehicles of Volkswagen, the further negotiations between the parties as well as regulatory approvals. Against this background, a final decision on the establishment of the joint venture has not been made yet. In case the joint venture would be established successfully, Volkswagen intends to make further investments in shares of Rivian Automotive, Inc., or in the joint venture in the total amount of $4B. The additional investment in shares of Rivian Automotive, Inc., would be made in two tranches of 1 billion USD each in 2025 and 2026 and would be contingent on Rivian Automotive, Inc., and the joint venture achieving certain milestones. With respect to the joint venture Volkswagen would provide a payment in the amount of 1 billion USD upon foundation of the joint venture in 2024 and grant a loan in the amount of 1 billion USD in 2026. If the joint venture will be successfully implemented and certain further milestones are achieved, the total investment of Volkswagen in shares in Rivian Automotive, Inc., as well as in equity and debt in the joint venture would aggregate in a total amount of 5 billion USD by 2026; a part of which in the amount of 2 billion USD would be paid out still in fiscal year 2024. The announced transaction could result in an unplanned cash outflow of up to 2 billion EUR in the current fiscal year. Therefore, Volkswagen AG is updating its financial forecast for fiscal year 2024 as follows: In the Automotive Division, Volkswagen AG now expects net cash flow to range between 2.5 billion EUR and 4.5 billion EUR (previously: 4.5 billion EUR to 6.5 billion EUR) and net liquidity between 37 EUR billion and 39 billion EUR.

16:06 EDT FedEx conducting assessment of role of FedEx Freight in portfolio structure - With the recent completion of the FY25 planning process, FedEx has turned its focus to the next phase of its long-term stockholder value-creation plans. As a part of this work, FedEx management and Board of Directors are conducting an assessment of the role of FedEx Freight in the company's portfolio structure and potential steps to further unlock sustainable shareholder value. The company is committed to completing this review thoroughly and deliberately, by the end of the calendar year. FedEx will conduct this assessment while continuing to focus on customers, team members, and the safety of its operations.

16:05 EDT Rivian jumps 23% to $14.44 after VW stake, joint venture announcement

16:04 EDT CPS Technologies announces Navy SBIR Phase II award - CPS Technologies Corporation announced that it has been awarded a Phase II SBIR contract from the U.S. Navy Air Systems Command, NAVAIR. With funding of more than $1M over 30 months, CPS will continue its development of novel metal matrix composites for thermal energy storage to address the requirements of NAVAIR's Advanced Anti-Radiation Guided Missile - Extended Range program.

19:37 EDT Intellia reports proof-of-concept data for redosing CRISPR-based therapy - Intellia Therapeutics (NTLA) presented new data demonstrating for the first time the potential for redosing with an investigational, in vivo CRISPR/Cas9 genome editing therapy. These data from the ongoing Phase 1 study of NTLA-2001, a single-dose treatment in development for transthyretin, or ATTR, amyloidosis, were presented at the Peripheral Nerve Society Annual Meeting, taking place June 22-25. NTLA-2001 is currently being evaluated in patients with either ATTR amyloidosis with cardiomyopathy, or ATTR-CM, or hereditary ATTR amyloidosis with polyneuropathy, or ATTRv-PN. Development and commercialization of NTLA-2001 is led by Intellia as part of a multi-target collaboration with Regeneron (REGN). Data from the Phase 1 trial has demonstrated that a one-time 55 mg dose of NTLA-2001 led to consistent, deep and durable reduction of serum TTR protein levels. This 55 mg dose was selected for further evaluation in the actively enrolling Phase 3 MAGNITUDE trial for ATTR-CM and the planned Phase 3 trial for ATTRv-PN. In the Phase 1 trial, the three initial patients enrolled in the dose-escalation portion received a 0.1 mg/kg dose of NTLA-2001, which led to a 52% median reduction in serum TTR by day 28. As expected, the 0.1 mg/kg dose resulted in lower-than-targeted serum TTR reduction. These patients were offered the opportunity to receive a follow-on dose of NTLA-2001 at the completion of the protocol-specified two years of observation. All three patients subsequently received a 55 mg dose, which led to the target pharmacodynamic effect and a 90% median reduction in serum TTR by day 28. The corresponding reduction from original baseline levels was a 95% median reduction in serum TTR. NTLA-2001 was generally well tolerated across all patients after receiving the follow-on dose. One of the three patients experienced a mild infusion-related reaction with the 55 mg dose. Safety and pharmacodynamics of the NTLA-2001 redosing were consistent with those observed after a single 55 mg dose. Further, favorable safety and tolerability continues to be observed, with patient follow-up beyond three years for the earliest dosed patient. "Today's data showcase an exciting new platform advancement for Intellia and the field of gene editing. For the first time ever, we demonstrated that redosing with CRISPR, utilizing our proprietary, non-viral LNP-based delivery platform, enabled an additive pharmacodynamic effect on the target protein," said Intellia President and Chief Executive Officer John Leonard, M.D. "While redosing is not planned for the NTLA-2001 program for the treatment of transthyretin amyloidosis, part of our commitment to patients enrolled in the dose-escalation portion of the Phase 1 study was to provide them with the opportunity to receive the therapeutic dose selected if they did not reach the target protein reduction level. These data provide platform proof-of-concept that we can re-dose, if necessary, enabling us to pursue treatment of other diseases where patients might need more than one dose to reach the desired therapeutic effect."

18:20 EDT Meta reveals new Threads' feature allowing more 'fediverse' sharing - Meta (META) CEO Mark Zuckerberg diclosed earlier on Tuesday that, "Starting today, people using Threads in 100+ countries can turn on sharing to the fediverse." Meta elaborated with a blog entry out earlier, that said in part: " A The fediverse is a global social network of interconnected servers that allows people to communicate across different platforms. Threads is Meta's first app built to be compatible with the fediverse to help people join public conversations and find their community, no matter what server they use...So what does that mean? The fediverse allows you to communicate across different servers - imagine posting on Threads and having people see your post on Tumblr or Flipboard. A helpful analogy is e-mail. If you use Yahoo and your friend uses Gmail, you're able to send emails to each other because both providers conform to the same protocol. Unlike email, your fediverse conversations and profile are public and can be shared across servers. Right now, most social networks don't work that way. People on Reddit (RDDT) can't follow people on Pinterest (PINS), for example....The fediverse changes that, enabling people to follow one another and communicate across different servers." Other companies in the social media space also include Snap (SNAP) and X, formerly Twitter (TWTR). Reference Link

17:59 EDT Morgan Stanley Energy Partners completes sale of Durango Permian to Kinetik - Investment funds managed by Morgan Stanley Energy Partners (MS) announced the closing of the sale of Durango Permian to a subsidiary of Kinetik Holdings (KNTK). Consideration for the Durango Permian sale includes a combination of cash and equity, including contingent consideration payable upon the successful commissioning of Durango Permian's Kings Landing Gas Gathering and Processing Development. Durango Permian, a subsidiary of Durango Midstream, is a gas gathering, processing, and carbon dioxide sequestration business operating in the Permian Basin of southeast New Mexico. Durango is majority-owned by funds managed by Morgan Stanley Energy Partners. Commenting on the transaction, Richard Cargile, President and Chief Executive Officer of Durango, said: "Durango is excited to announce the completion of the sale of its Permian Basin assets to Kinetik. I am very proud of the dedication and tireless efforts of our employees as we have expanded our presence in New Mexico through two acquisitions and multiple growth projects in partnership with Morgan Stanley Energy Partners over the last five years. We share in Kinetik's enthusiasm for the sustained growth potential of Durango's operating region and for the Kings Landing project, which will provide a critical gas processing and treatment solution for the region's producers. The Company's assets are complementary to Kinetik's existing operating footprint, expand Kinetik's presence in New Mexico, and reinforce Kinetik's value proposition as a pure-play midstream provider across the entire Delaware Basin. The combination of assets is expected to realize significant operating synergies and capture economies of scale benefits. The base business provides strong stable earnings and the commissioning of Kings Landing supports significant future growth in the area."

17:15 EDT Augmedix says Go ED has met HCA's criteria for expansion - In a regulatory filing, Augmedix (AUGX) disclosed that John Doulis, VP of Data Services and Innovation for the Clinical Transformation & Innovation division of HCA Healthcare (HCA), will have a fireside chat today, June 25, at 1:00 p.m. Central Time with Ryan Daniels, an equity analyst and Partner at William Blair. This discussion will be open to investors and clients of William Blair. John and Ryan will be discussing the strategic relationship of Augmedix with HCA Healthcare. "The discussion will include comments that Augmedix Go ED, the company's fully automated AI documentation product for emergency departments, has met HCA's criteria for expansion. This criteria set is comprised of rigorous metrics relating to Augmedix Go technical performance, feature release milestones, and clinician feedback scores. Further, John Doulis will engage in discussion around HCA's focus on building out AI solutions for enterprise-scale and systematized steps now being taken to embark on broader rollouts of Augmedix Go, given that HCA's acceptance criteria are now met," the filing stated. Reference Link

12:01 EDT Tronox falls -9.9% - Tronox is down -9.9%, or -$1.83 to $16.71.

12:01 EDT Cheetah Mobile falls -12.9% - Cheetah Mobile is down -12.9%, or -69c to $4.67.

12:00 EDT Carnival plc rises 8.4% - Carnival plc is up 8.4%, or $1.23 to $15.90.

11:54 EDT Connexa Sports Technologies announces 1-for-20 reverse stock split - Connexa Sports Technologies announced that it will effect a 1-for-20 reverse stock split of its common stock, par value $0.001 per share. The common stock will continue to be traded on Nasdaq under the symbol "YYAI" and will begin trading on a reverse split-adjusted basis when the market opens on June 27. Post-reverse split, the number of the company's outstanding shares will be 2,042,669. The reverse stock split is intended to increase the market price of the company's common stock to regain compliance with the minimum bid price requirement for continued listing on Nasdaq, but there can be no assurance that the reverse split will have such effect. Following the reverse split, the company must see a closing bid price of its common stock of at least $1.00 per share for a minimum of ten consecutive trading days in order to regain compliance with the minimum bid price requirement for continued listing on Nasdaq.

15:19 EDT Waymo opens driverless robotaxi service to everyone in San Francisco - In a blog post, the Waymo team said, "The wait is over. Starting today, anyone can hail a ride with Waymo in San Francisco. Rain, shine, or Karl the Fog, just download the app, and ride. We've been operating in San Francisco for years now, deliberately scaling our service over time. With tens of thousands of weekly trips, our Waymo One service provides safe, sustainable, and reliable transportation to locals and visitors to the city alike. Now it's available to anyone." Reference Link

11:09 EDT ZimVie jumps 14% to $16.91 after Bloomberg report

11:05 EDT Revolve Group acquires majority stake in Alexandre Vauthier - REVOLVE Group has acquired a majority stake luxury fashion brand, Alexandre Vauthier. The company said, "The strategic move further differentiates REVOLVE Group, Inc. in the premium and high-end fashion market, taking a significant step forward in its mission to redefine the fashion landscape...Renowned for its couture designs and impeccable craftsmanship, Alexandre Vauthier has carved out a distinguished position within the luxury fashion sphere. With a successful track record in FWRD's luxury brand portfolio and a strong resonance with its sophisticated customer base, Alexandre Vauthier embodies elegance, innovation and luxury. This exciting partnership between REVOLVE Group, Inc. and Alexandre Vauthier presents an opportunity to leverage each other's strengths. By integrating REVOLVE and FWRD's cutting-edge marketing strategies, data-driven merchandising techniques, and renowned operational infrastructure with Alexandre Vauthier's iconic brand identity and exceptional craftsmanship, the collaboration aims to propel Alexandre Vauthier to new heights within the luxury fashion landscape." As part of the transaction, Revolve Group, Inc. will contribute purchased assets to a newly formed entity and will invest EUR 6M over three years. Additional terms were not disclosed.

15:02 EDT Keysight says Samsung Semiconductor India Research selects S-FTL solution - Keysight Technologies (KEYS) announces that Samsung (SSNLF) Semiconductor India Research has selected the Keysight Signaling Field-To-Lab solution to streamline and automate its 5G field-to-lab workflow in its Bengaluru lab. The comprehensive, end-to-end 5G wireless protocol signaling solution improves end-user quality of experience by accelerating the replication, analysis, and resolution of 5G field issues in a test lab environment

10:23 EDT Nano Nuclear Energy Inc trading resumes

10:18 EDT Nano Nuclear Energy Inc trading halted, volatility trading pause

10:03 EDT Eli Lilly collaborates with OpenAI to discover novel antimicrobials - Eli Lilly and Company announced a collaboration with OpenAI that will allow Lilly to leverage OpenAI's generative AI to invent novel antimicrobials to treat drug-resistant pathogens. Antimicrobial resistance is one of the top public health and development threats across the global health landscape. AMR affects countries in all regions and at all income levels and is exacerbated by poverty and inequality, particularly in low- and middle-income countries, which results in the greatest impact and risk. The misuse and overuse of antimicrobials in humans, animals and plants are the main drivers in the development of drug-resistant pathogens, magnifying this threat to global health.

10:01 EDT Owens & Minor falls -8.2% - Owens & Minor is down -8.2%, or -$1.33 to $14.84.

10:00 EDT Li-Cycle falls -10.7% - Li-Cycle is down -10.7%, or -71c to $5.95.

10:00 EDT Carnival rises 6.8% - Carnival is up 6.8%, or $1.11 to $17.50.

10:00 EDT PHI Group files provisional patent application for multi-impulse energy system - PHI Group announced that a Provisional Patent Application has been filed with the United States Patent and Trademark Office, Application Number #63/655,846; Docket # 24RMA07, for a new and useful invention entitled "MULTI-IMPULSE ENERGY SYSTEM." The requirements of law have been complied with, and therefore, the invention disclosed in the above referenced U.S. provisional patent application is legally "Patent Pending" within the United States of America.

09:58 EDT MicroAlgo Inc trading resumes

09:53 EDT MicroAlgo Inc trading halted, volatility trading pause

09:48 EDT Pentair falls -6.3% - Pentair is down -6.3%, or -$5.01 to $74.99.

09:47 EDT Owens & Minor falls -16.0% - Owens & Minor is down -16.0%, or -$2.59 to $13.58.

09:47 EDT Mizuho Financial Group rises 3.5% - Mizuho Financial Group is up 3.5%, or 14c to $4.09.

09:47 EDT Modiv rises 4.7% - Modiv is up 4.7%, or 67c to $14.97.

09:45 EDT HPH announces Puyi Fund assets under advice surpass RMB 24B - Highest Performances Holdings announces that its Puyi Fund's assets under advice for its asset allocation services reached RMB 24.7 billion as of June 21, 2024, reflecting a remarkable year-on-year growth of 188%. This substantial increase in scale showcases significant growth for the fund. The company said, "This accomplishment is primarily attributed to the Puyi Fund's service philosophy, 'long-term commitment to clients and clients' long-term benefits," introduced in 2023, as well as the ongoing efforts of the Company in adjusting its product strategy and embracing digital transformation. On one hand, the Company implemented a comprehensive family wealth management account system, redirecting its flagship products towards fixed-income funds and fund portfolios to enhance clients' perception of wealth acquisition. On the other hand, the Company has elevated its overall service standard through digital transformation, greatly improving the client's investment experience."

09:41 EDT Regis trading resumes

09:39 EDT Sunrise New Energy secures order from Times Geely - Sunrise New Energy announced the acquisition of a significant new client, Times Geely Power Battery, which will commence with a substantial monthly order of 300 tons of anode materials for power batteries. Times Geely is a joint venture between CATL and Zhejiang Geely Holding Group.

13:37 EDT Tempus AI, United Therapeutics collaborate to study use of AI to detect PH risk - Tempus AI (TEM) announced a new collaboration with United Therapeutics (UTHR). As part of this collaboration, Tempus will develop and investigate AI-based medical device software to detect patients at risk of having undiagnosed pulmonary hypertension. PH is a fatal, progressive disease of the heart and lungs that affects approximately 1% of the population. Despite an increasing number of available treatments for the disease, the detection or clinical diagnosis of PH is typically delayed for 2 or more years. To help solve this critical problem, Tempus built an algorithm that automatically analyzes the results of a 12-lead electrocardiogram to identify patients at risk of undiagnosed PH to be further evaluated by clinicians. The initial findings from this work were recently presented at the American Thoracic Society International Conference in San Diego, California on May 22, 2024. Tempus' research and development program will leverage Tempus Next, the company's AI-enabled care pathway intelligence solution, to facilitate the deployment of the algorithm at participating centers. Clinicians will evaluate its ability to detect patients at risk of undiagnosed PH, and to track clinical outcomes of patients who are identified for further evaluation, within a prospective clinical study at up to 60 centers. Tempus and UT plan to collaborate on this study to investigate the clinical impact of this technology and gain new insights into the detection and diagnosis of PH. Tempus expects to engage with the Food and Drug Administration to align on regulatory requirements and FDA expectations regarding validation of this novel AI-based algorithm.

09:37 EDT Knightscope announces renewal of K5 contracts by two clients - Knightscope announced that two more clients have renewed contracts for their K5 Autonomous Security Robot service. A commercial real estate property in California renewed for the third year, and a healthcare provider in New York renewed for a second year, Knightscope said.

09:33 EDT Tyler Technologies opens new manufacturing facility in Kingston Springs - Tyler Technologies announced the grand opening of its new manufacturing facility in Kingston Springs, Tennessee, to support the growth of its Enterprise Corrections software, including administration, financial management, communications, and re-entry solutions.

09:32 EDT JFrog to acquire Qwak AI to streamline AI models - JFrog announced it has entered into a definitive agreement to acquire Qwak AI, creators of the AI and MLOps platform. With the acquisition, JFrog aims to offer a unified and scalable solution for DevOps, Security, and MLOps stakeholders. This advanced, industry-leading MLOps functionality is designed to free data scientists and developers from infrastructure concerns, accelerating the creation and delivery of AI-powered applications. JFrog is the single system of record for all software packages, including models stored in Artifactory. Enhancing its machine learning model capabilities will enable users to streamline models from development to deployment.

09:31 EDT Hyatt expands brand presence in New Orleans with two new hotels - Hyatt Hotels Corporation announced the expansion of Hyatt's brand presence in New Orleans with Maison Metier and The Barnett, which have joined the Hyatt portfolio as affiliated hotels. The hotels are expected to join Hyatt's Independent Collection of brands and participate in the World of Hyatt loyalty program this year. The two properties are owned by The Domain Companies and managed by HRI Hospitality.

13:30 EDT The Digital Dept. selected by Crocs to execute influencer program - The Digital Dept. announced its selection by Crocs to execute a comprehensive influencer strategy for Crocs' latest product line, the Getaway Sandals. Through their work with brands like Crocs and other major companies, The Digital Dept. solidifies its position as a key player in the $24 billion influencer marketing industry. This full-funnel marketing approach for Crocs Getaway Sandals leveraged influencers to drive engagement across both paid and earned channels. The campaign ran from April to June 2024, and upon completion, the Crocs S2 Getaway Sandals influencer program successfully garnered more than 5 million impressions, a reach of 3.9 million, 248,000 engagements, and over 13,000 link clicks.

09:27 EDT Rail Vision receives $200K follow-on order from rail and leasing services firm - Rail Vision announced a follow-on order from one of its customers, a leading US-based rail and leasing services company. The Company announced at the beginning of 2024, it has signed a contract valued at up to $5M for ShuntingYard products. In April 2024, Rail Vision received an initial purchase order amounting to approximately $1 million as part of the contract, with the additional $4 M of follow-on orders subject to customer approval. The current follow-on order, in the amount of approximately $200,000, is in addition to the existing contract, and refers to additional services requested

09:25 EDT Thumzup welcomes Chip Cookies to AdTech platform - Thumzup Media Corporation welcome dChip Cookies, located at 10716 Jefferson Blvd, Culver City, as one of its most recent advertising partners on its proprietary social media AdTech platform. Chip Cookies recently opened up Culver City in March 2024. Each week, the menu features a variety of cookie flavors on rotation. Those seeking warm, homemade cookies now have the unique opportunity to earn money by sharing about their experience through the Thumzup app.

09:23 EDT LegalZoom partners with BusinessLoans.com - LegalZoom.com is announcing its newest partnership with BusinessLoans.com to provide more streamlined access to capital for small business owners. BusinessLoans.com, positioned as a marketplace across lenders, provides small businesses with options such as secured loans, business credit cards, and credit-building products tailored to their stage, all within the LegalZoom platform. By focusing on credit-building strategies, BusinessLoans.com helps enhance personal and business credit profiles, enabling entrepreneurs to secure essential funding and build a solid credit foundation for future funding and growth opportunities. Each product is designed to meet the unique needs of small businesses, ensuring they have access to the financial resources necessary for success and expansion. Through the embedded partnership, customers can launch a BusinessLoans.com application that will match them with funding options available without having to leave the LegalZoom site. In addition, LegalZoom's simplified questionnaire and guided process delivers a customized experience that makes it easy for customers to save time and improve accuracy.

09:21 EDT Hovnanian announces credit rating upgrade from Moody's - Hovnanian Enterprises announced that Moody's Ratings has upgraded Hovnanian's corporate family rating to B2 from B3. In a press release issued on June 24, 2024, Moody's cited an improvement in the company's leverage profile through solid operating performance and growth in net worth, as well as through the recently completed debt exchange transaction. Moody's outlook for Hovnanian remains stable.

09:20 EDT Cabot details sustainability performance in 2024 Sustainability Report - Cabot Corporation published its 2024 Sustainability Report, which details the progress it has achieved on advancing its sustainability objectives. "As we continue to make advancements toward a lower carbon future, we recognize the critical importance in reducing the GHG emissions across our entire value chain, and that starts with understanding where the opportunities are," said Martin O'Neill, senior vice president, Safety, Health and Environment and Government Affairs; chief sustainability officer. "In 2023, we completed a comprehensive inventory of our Scope 3 GHG emissions, while making great progress on our 2025 GHG Scope 1 and Scope 2 intensity reduction goal."

09:19 EDT Viant expands carbon measurement capabilities with Cedara - Viant Technology announced a strategic integration with the carbon intelligence platform Cedara. This partnership aims to provide comprehensive carbon measurement capabilities for advertisers as well as for Viant's own corporate emissions. This integration marks the latest advancement for Viant's flagship sustainability program, Adtricity, enabling advertisers to drive improved carbon efficiency through Viant's platform.

09:18 EDT Carnival sees Q3 adjusted EBITDA up 20% y-o-y to $2.66B - Sees Q3 adjusted net income up 35% y-o-y to $1.58B.

09:18 EDT Carnival sees 2024 adjusted EBITDA up 40% y-o-y to $5.83B - Sees 2024 adjusted net income $1.55B.

09:16 EDT Nuwellis announces granting of USPTO patent for CRRT, Vivian - Nuwellis announced the recent grant of a new patent from the United States Patent and Trademark Office USPTO related to its groundbreaking pediatric continuous renal replacement therapy CRRT , Vivian . This patent covers critical advancements that will significantly improve the performance and user experience of Vivian. This is the second of several forthcoming patents for Vivian, underscoring Nuwellis' commitment to development of novel technology designed to improve treatment options for critically ill children.The patent claims, include self-centering fluid bag hangers and density compensation mechanisms for enhanced accuracy in fluid management. Ease of use is increased with self-sealing access ports for easy configuration of various dialysis modes, streamlining the treatment process. Additionally, reliability is boosted by a temperature-adjusting auto-clamp that ensures secure seals, reducing the risk of leaks and enhancing overall system dependability. "We are thrilled to announce the issuance of this patent, which represents a significant milestone in the development of our pediatric continuous renal replacement therapy, Vivian," said Nestor Jaramillo, President and Chief Executive Officer at Nuwellis. "These innovations not only reinforce our position as a leader in fluid management solutions but also highlight our dedication to advancing technology that can make a real difference in the lives of thousands of pediatric patients across the U.S. Our focus on increased accuracy, ease of use, and reliability will help ensure that children receiving critical care have access to the best possible treatment options."

09:14 EDT IGC Pharma's TGR-63 preclinical results show reduction in amyloid plaque - IGC Pharma announced encouraging preclinical results in an Alzheimer's mouse model demonstrating the potential of the Company's therapeutic candidate, TGR-63, to combat Alzheimer's disease. In a mouse model of Alzheimer's, TGR-63 treatment led to a substantial reduction of amyloid plaque. Compared to untreated mice, TGR-63 treatment reduced plaque deposits by 78% in the cortex, a critical brain region for memory and cognition, and by 85% in the hippocampus, which plays a central role in learning and memory. These findings suggest TGR-63's potential to slow or even reverse the progression of Alzheimer's disease.

09:13 EDT Mattel says 80% of games portfolio will be colorblind accessible by end of 2024 - Mattel announced that 80 percent of its global games portfolio will be colorblind accessible by the end of the year, and 90 percent in 2025, as part of its commitment to create more inclusive play experiences. This shift will include the UNO brand, and many more such as Phase 10, DOS, Blokus, and Tumblin' Monkeys games.

09:11 EDT Hyperfine announces two presentations at AAIC - Hyperfine announced that two presentations on the clinical utility of portable ultra-low-field MRI for Alzheimer's disease monitoring have been accepted in the developing topics poster sessions at the upcoming 2024 Alzheimer's Association International Conference, AAIC, July 28-August 1 in Philadelphia. "With the recent developments in Alzheimer's therapies and care, the medical community has shown tremendous interest in incorporating portable ultra-low-field MR brain imaging into the continuum of care for Alzheimer's patients, taking advantage of the system's versatility to scan in diverse professional care settings. We are very excited to be attending the AAIC conference for the first time this year in Philadelphia," said Maria Sainz, President and CEO of Hyperfine.

09:10 EDT ESS's iron flow batteries selected by Indian Energy, CEC - ESS Tech announced that it will participate in the Rapid Integration and Commercialization Unit, RICU, at Marine Corps Air Station Miramar. The RICU is a living laboratory for testing how leading LDES technologies can be integrated into utility-scale microgrid applications. The RICU is a venture between Indian Energy, the California Energy Commission, CEC, and the Department of Defense, DOD, to validate LDES technologies. Phase 2 of research at the RICU was funded by the CEC in May 2024 through a $4.85M agreement between the CEC and Indian Energy to demonstrate the diverse capabilities of LDES technologies. The partnership with Indian Energy lays the foundation for deployment on CEC grants and DOD installations.

09:09 EDT MetLife, GeoBlue announce they will offer joint solution - MetLife and GeoBlue announced they will offer a full suite of expatriate benefit products in a best-in-class single solution, Globaline. Globaline brings together health coverage and services from GeoBlue - including medical, dental, vision, prescription, wellness, international employee assistance program and political and natural disaster assistance - and life, accidental death & dismemberment and long term disability coverage from MetLife Worldwide Benefits, including value-added services, such as grief counseling, will preparation & digital estate planning and estate resolution.

09:08 EDT Blue Star Foods secures land-based aquaculture license renewal - Blue Star Foods has been granted an extension renewal for the land-based aquaculture license thru 2033. All parts of this license are issued under the authority of the Fisheries Act and confer, subject to provisions of the Fisheries Act and Regulations made there under, the authority to carry out aquaculture activities including cultivation and harvest of fish. The license renewal encompasses the Taste of BC Aquafarms located at 2948, 2930 and 2934 Jameson Road. The aquaculture license covers white sturgeon, coho salmon, chinook salmon and rainbow trout.

13:07 EDT NextNav appoints Nicola Palmer to board of directors - NextNav (NN) announced the appointment of Nicola Palmer to its Board of Directors effective June 24, 2024. Palmer has also been appointed as a member of the Audit Committee of the Board. Following this appointment, the Board is now comprised of seven directors. As Chief Product Officer of Verizon (VZ), Palmer led the organization's broad technical capabilities and assets to innovate, develop, and rapidly deliver a portfolio of products and services for customers of all Verizon businesses and oversaw the identification, development, acquisition, and application of new technologies to advance network capabilities.

09:07 EDT Verra Mobility, Hayden AI announce partnership - Verra Mobility and Hayden AI announced a partnership to offer next-generation technology solutions to customers across the U.S. Together, the two companies will deliver a seamless technology platform designed to improve road safety, sustainability, and public transit reliability and accessibility. The partnership will leverage Hayden AI's mobile perception technology and Verra Mobility's customer integration experience to provide cities and transit agencies with a best-in-class program for automated bus lane, bike lane, bus stop, and double-parking enforcement solutions.

09:05 EDT Safety Shot announces strategic partnership with Chip Quigley, Ari Freedman - Safety Shot proudly announces a strategic partnership with Chip Quigley, founder and CEO of Kingdom Entertainment Group, and Ari Freedman, a seasoned executive from Surge Brands, to advise across the brand's marketing and events, and brand development and distribution respectively.

09:05 EDT GSE Systems awarded contracts by U.S. utility for over $700K - GSE Systems announced contracts worth more than $700K for the provision of services related to Flow Accelerated Corrosion - FAC - and Erosion programs for a large east-coast utility based in the U.S. Power plants must regularly carry out License Renewal activities to prepare for Subsequent License Renewals. Upgrades to the FAC and Erosion programs become necessary. The agreement requires GSE to carry out the specified Scope of Work from Fall 2024 to Spring 2030. GSE has been supporting this client since 2017 and is well-acquainted with the client's FAC procedures, protocols, locations, and staff members.

09:05 EDT PubMatic hires two executives for commerce media team - PubMatic announced the addition of two executives to its commerce media team. These strategic hires will play a crucial role in advancing PubMatic's Convert product and expanding its impact across the commerce media landscape. Tim Rogers, Vice President of Commerce Media, will report to Amar Goel, the company's Founder, Chairman, and CIO, and lead PubMatic's global commerce media strategy, focusing on revenue growth and strengthening the company's market position. Rogers brings more than twenty years of commercial leadership and innovation within advertising technology, previously serving as the SVP of Enterprise Go-To-Market Strategy at Criteo. Somesh Bindu, Vice President of Commerce Media Product Management, will report to Nishant Khatri, the EVP of Product Management. Bindu will serve as the Commerce Media Product leader, drive product strategy, and ensure strong execution across Convert and PubMatic's Commerce and Retail Media product portfolio. He brings extensive expertise from his product-focused leadership roles at Amazon Advertising and, most recently, Walmart Connect.

13:04 EDT Grubhub partners with Albertsons for nationwide grocery delivery - Grubhub (TKWY) and Albertsons Companies (ACI) have partnered to bring nearly 1,800 Albertsons Cos. stores to Grubhub's Marketplace for delivery including Albertsons, Safeway, Vons, Jewel-Osco, Shaw's, ACME and Tom Thumb. Availability is based on delivery locations through the Grocery section on the Grubhub app and website.

09:02 EDT Markel to acquire majority interest in Valor, terms not disclosed - Markel Group and Valor Environmental announced that they have entered into a definitive agreement for Markel Group to acquire a majority interest in Valor and its related operating companies. The transaction is subject to customary closing conditions and is expected to close in the second quarter of 2024. Additional terms were not disclosed.

09:02 EDT Hamilton Global Specialty appoints O'Brien as Chief Actuary - Hamilton Global Specialty, an underwriting platform of Hamilton Insurance Group, announced that Niamh O'Brien has been appointed as Chief Actuary, effective June 1, 2024. O'Brien reports to Wilfred Chin who was recently promoted to Group Chief Actuary at Hamilton.

08:59 EDT LPL Financial: Danielle Qualls joins broker-dealer, RIA, custodial platforms - LPL Financial announced that financial advisor Danielle Qualls has joined LPL Financial's broker-dealer, RIA and custodial platforms, teaming up with existing firm Bergkamp Financial. She reported having served approximately $160 million in advisory, brokerage and retirement plan assets and joins LPL from Stifel, Nicolaus and Co. A Kansas native, Qualls started her career in corporate accounting before making the switch to wealth management in 1999. She focuses on connecting with clients at a multigenerational level to develop financial strategies aimed at building family legacies. Looking to extend that collaborative approach to a team setting while enjoying the benefits of independence, Qualls turned to LPL to help find an established practice that fit her goals, clients and personality. This led her straight to women-led Bergkamp Financial.

08:57 EDT Century Communities announces new partnership with Kohler Co. - Century Communities is pleased to announce a new partnership with Kohler Co., equipping all new Century Communities homes with Kohler kitchen faucets, bathroom faucets, and shower heads for both of the company's homebuilding brands: Century Communities and Century Complete.

08:51 EDT Crown Electrokinetics announces commencement of work in Oregon - Crown Electrokinetics announced that its Crown Fiber Optics division has commenced work in Oregon. The new opportunity is made up of both fiber construction, and underground power infrastructure. Through multiple prime contracts, Crown expects this market to generate as much as $8 million in revenue in 2024, with the potential to reach $15 million in 2025. These prime contracts will consist of directional drilling, excavation, micro trenching, and splicing.

08:49 EDT Safety Shot announces partnership with Chip Quigley, Ari Freedman - Safety Shot announces a strategic partnership with Chip Quigley, founder and CEO of Kingdom Entertainment Group, and Ari Freedman, an executive from Surge Brands, to advise across the brand's marketing and events, and brand development and distribution respectively.

12:48 EDT Wearable Devices announces results on Lenovo's XR Headset using Mudra tech - Wearable Devices announced demonstrations of its Mudra technology on Lenovo's ThinkReality XR headset, at the Augmented World Expo 2024. This demonstration with Lenovo's advanced extended reality hardware based on Qualcomm's Snapdragon Chipset and Spaces engine showcased the potential for enhanced user interaction and engagement. Attendees of AWE 2024 had the unique opportunity to experience the seamless integration of Wearable Devices' Mudra technology with Lenovo's ThinkReality headset. This integration leverages the advanced neural input technology developed by Wearable Devices to provide natural and intuitive control within XR environments, offering users a more immersive and interactive experience.

08:45 EDT Alliance Entertainment's popmarket partners with Tsuburaya Productions - Alliance Entertainment Holding announced a partnership with Tsuburaya Productions for the upcoming San Diego Comic-Con, July 25-28, 2024. Alliance Retail's popmarket e-commerce site will run the on-site retail operations at the ULTRAMAN booth on the main convention floor, offering collectibles, posters, and Blu-ray and SteelBook products for sale to attendees. The ULTRAMAN booth will feature products from Bandai, Nakatomi, and AEC's Mill Creek Entertainment division.

08:44 EDT Airship awarded contract extension within DOJ, no terms given - Airship AI Holdings has been awarded a contract extension within the Department of Justice DOJ for the Company's Acropolis Enterprise Sensor Management video and data management platform supporting emerging public safety and investigative requirements. "This award represents the critical nature of our Acropolis and Outpost AI platforms to the agency's daily operations investigating and countering threats to national security and the homeland," said Paul Allen, President of Airship AI. "The agency's continued trust in Airship AI to support its operations is a reflection of the strength of the platform as well as the internal team here at Airship AI dedicated to ensuring the agency's mission success. We take great pride in knowing that the products we put out into the marketplace are making a difference on a daily basis here and abroad."

08:43 EDT Gaxos.AI completes development of AI solution for developers, publishers - Gaxos.ai announced that its gaming division, has completed development of its AI solution for game developers and publishers. The product has currently moved from initial development to closed beta and is being tested and used by independent developers of different experience levels and styles. The Company will work towards providing developers with improved usage and AI tools based on the closed beta and feedback.

08:41 EDT Alpha Tau publishes long-term safety, efficacy data in superficial cancers - Alpha Tau Medical announced the publication of an article entitled "Extended Follow-Up Outcomes from Pooled Prospective Studies Evaluating Efficacy of Interstitial Alpha Radionuclide Treatment for Skin and Head and Neck Cancers" in the journal Cancers, with further detail on data previously announced by the Company in August 2023. The publication was authored by clinical investigators from Israel, Italy and the United States. The aim of the analysis was to evaluate the long-term toxicity outcomes and disease control rates for patients treated with Alpha DaRT and followed for up to four years. In this pooled analysis of 81 treated head and neck, oral cavity and skin tumors from four clinical trials with a median follow-up of 14 months, the overall response rate was 99%, with a complete response observed in 89% of treated lesions, a 10% partial response rate, and one patient non-evaluable. Two-year local recurrence-free survival was 77%, and there were no grade 2 or higher late toxicities observed. Clinical variables, including recurrent versus non-recurrent lesions, baseline tumor size, or histology, did not impact long-term outcomes. The published results indicate that the Alpha DaRT treatment may provide tumor control even beyond the acute treatment period of short-term local responses, potentially leading to longer-term disease control. The lack of moderate or severe toxicities observed in this analysis is promising and suggests that Alpha DaRT may potentially offer an appropriate long-term treatment for these very difficult-to-treat cancers. Further follow-up and additional clinical studies are ongoing and will provide additional characterization of the safety and efficacy profile of Alpha DaRT.

08:37 EDT Capricor Therapeutics announces Pre-BLA meeting for CAP-1002 - Capricor Therapeutics announced that the U.S. Food and Drug Administration has scheduled a Pre-BLA meeting with the Company in the third quarter of 2024 for deramiocel, for the treatment of Duchenne Muscular Dystrophy. Capricor's goal for this meeting will be to finalize its BLA filing plans based on all currently available data as well as to work with the FDA to outline the rolling BLA submission timeline.

08:36 EDT Lead Real Estate enter business alliance agreement with Samurai Capital - Lead Real Estate has entered into a business alliance agreement with Samurai Capital Co., Ltd. an ESG-conscious real estate investment company also based in Tokyo. As per the agreement, which was signed on May 30, 2024, a trust beneficiary interest purchase agreement totaling approximately 4.1 billion Japanese yen, or about $26.1 million, was concluded.

08:35 EDT Aclarion expands commercial agreement with the London Clinic - Aclarion is extending their commercial agreement with the prestigious London Clinic in London, UK. The contract extension establishes a higher price point for Nociscan, engages The London Clinic to secure payer coverage decisions from leading private health insurers, and aligns Aclarion with The London Clinic in expanding access to referring physicians throughout the greater London market. The initial contract with The London Clinic was aimed at allowing The London Clinic physicians to evaluate the clinical value of Nociscan in treating their chronic low back pain patients. After utilizing Nociscan in just 20 patients, the physicians saw enough value to support a contract extension aimed at increasing access to Nociscan for patients. Increased access is being pursued through outreach to referring physicians, increasing the reimbursement to Aclarion, and approaching the payer community to secure private insurance coverage for Nociscan.

08:34 EDT Safe & Green expands agreement for modular electrical distribution centers - Safe & Green Holdings announced that Safe & Green Holdings has received an expansion of an agreement to manufacture seven additional container based electrical distribution centers as part of a multi-unit order for a client serving the big box retailer market. These units are in addition to the four units which the Company has already begun production.

08:33 EDT BIO-key says Los Angeles LGBT Center selects PortalGuard plaform - BIO-key International announces that Los Angeles LGBT Center with 17 locations and nearly 800 employees has selected its PortalGuard platform for secure, streamlined desktop sign-in that meets regulatory and insurance compliance requirements. The most prominent LGBTQ+ organization in the world, the Center offers programs, services, and advocacy spanning four areas: Health, Social Services and Housing, Culture and Education, and Leadership.

08:32 EDT Sidus Space, NamaSys Bahrain sign MOU to establish 'Sidus Arabia' JV - Sidus Space announced the execution of a Memorandum of Understanding, MOU, outlining its collaboration with NamaSys, a multi discipline Technology & Electronic Security Consultancy for the establishment of a joint venture, JV, with a mission to build, own and operate a satellite manufacturing, production, assembly and integration facility in the Middle East supporting Gulf Cooperation Council, GCC, countries and beyond. The MOU outlines that the parties intend to serve and fulfill the needs and requirements of government and private clients across the Middle East and North Africa region while sharing a unified mission of fostering science and technology development.

08:32 EDT Alexandria Real Estate announces long-term 127,382 RSF lease - Alexandria Real Estate announced that a top 20 pharmaceutical company and longstanding credit tenant has increased its San Diego footprint by nearly 53% with the execution of a 10-year lease for 127,382 RSF, with significant expansion options, for a new R&D center at 10075 Barnes Canyon Road on the SD Tech by Alexandria mega campus in the Sorrento Mesa submarket of San Diego. Purposefully curated to enable its tenants to attract, retain and inspire top talent, this mega campus provides an exceptional suite of bespoke amenities, which include multiple eateries, a health and wellness center, premier meeting and conference spaces, an expansive lawn and a seven-acre central park. With this strategic anchor lease, the 253,079 RSF Class A+ development, which is targeting LEED Gold Core & Shell and Fitwel certifications, is now 70% leased ahead of its anticipated initial delivery in 2025. The lease also brings Alexandria's 1.2 million RSF pipeline of under construction mega campus development projects in San Diego to 94% leased, demonstrating the advantages of the company's differentiated mega campus platform and leading life science industry brand.

08:31 EDT AST SpaceMobile announces strategic realignment of executive team - AST SpaceMobile announced a strategic realignment of its executive leadership team including the appointment of Scott Wisniewski, who currently serves as Chief Strategy Officer, to the additional role of President, Shanti Gupta, who currently serves as Chief Accounting Officer, as Chief Operations Officer, and Andrew Johnson, who currently serves as Chief Legal Officer, to the additional role of Chief Financial Officer. The strategic realignment is designed to leverage the proven track record of members of AST SpaceMobile's existing leadership and position the company for success in its next phase of accelerated growth.

08:29 EDT Skeena Resources secures $750M project financing package - Skeena Resources has secured a financing package totaling $750 millionwith Orion Resource Partners for the development, construction, and general working capital required to advance the Company's 100%-owned Eskay Creek Gold-Silver Project. This complete funding package significantly de-risks the Project and provides Skeena with optionality, flexibility and stakeholder alignment as the Company progresses Eskay towards production in the first half of 2027. The package provides a significant portion of financing prior to Skeena's receipt of required permits in respect to the Eskay project and therefore, allows the Company to advance the project on the most efficient and expedient schedule to production. Financing Package Highlights: The total financing package of $750 million is comprised of an equity investment, gold stream, senior secured loan, and a cost over-run facility: $100 million equity investment priced at a meaningful premium to the Company's five-day volume weighted average share price. $200 million gold stream with option to buy back up to 66.7% for 12-month period after start of commercial production. $350 million of committed capital available from a senior secured loan with 1% standby fee and no break fee. $100 million cost over-run facility in the form of an additional gold stream subject to the same standby terms as the Senior Secured Loan.

08:26 EDT Ingersoll-Rand appoints Scott Watson as GM, Life Science Technologies platform - Ingersoll Rand announced Scott Watson, former COO of ILC Dover, to serve as the senior vice president and general manager of the Life Science Technologies platform, effective immediately. He succeeds Corey Walker, who left the company to pursue an external opportunity. Scott is responsible for delivering ILC's global strategy across commercial, operations, and new product development activities, and as of January 1, 2025, leadership over the legacy Ingersoll Rand medical business.

08:23 EDT LifeMD launches private health insurance acceptance for primary care services - LifeMD announced the launch of private health insurance acceptance for its virtual primary care services, including weight management for medically qualified patients. Initially available in select states, the company plans to continue enrollments with private payors to facilitate access to medically necessary services, ultimately having broad coverage options across all 50 states. As part of its early 2025 roadmap, LifeMD expects to begin accepting Medicare. The acceptance of private insurance to cover medically necessary services is being offered to patients in connection with a monthly membership for non-covered services, with an out-of-pocket cost for those services that is considerably lower than current monthly self-pay fees. Once a patient's health insurance benefits have been electronically verified, LifeMD will handle the claims submission and prior authorization processes.

08:21 EDT Aquestive reports topline data from temperature/pH study of Anaphylm - Aquestive Therapeutics released topline pharmacokinetic data from the temperature / pH study of its product candidate Anaphylm Sublingual Film. Anaphylm is the Company's first and only orally administered epinephrine prodrug product candidate under development for the treatment of severe life-threatening allergic reactions, including anaphylaxis. The single-dose, five-period, randomized crossover study was designed to compare the PK and pharmacodynamics of Anaphylm just after consuming normal water, lemon water, and baking soda water. The primary PK parameters were the maximum amount of epinephrine measured in plasma and exposure, or the area under the curve, at various times after dosing, in 30 healthy adult subjects. Topline PK data from the study showed no statistically significant difference in PK results based on changes in temperature and pH. The most consumed beverages, such as soda, milk, coffee, and juice, have acidity between lemon water and normal water. While not statistically significant, alkaline substances like baking soda showed a somewhat higher absorption level than room-temperature water. The table below provides the ratio of Cmax and AUC 0-60min following administration of Anaphylm under various test states when compared to room temperature water. The Company's remaining supportive studies, inclusive of the self-administration study and the oral allergy syndrome challenge study, are all underway. The self-administration study's dosing is expected to conclude in the second quarter of 2024, and the OAS challenge study's initial dosing is expected to occur in July 2024. The table below indicates the remaining clinical studies anticipated before submission of the New Drug Application for Anaphylm.

08:18 EDT Immutep signs exclusive license agreement with Cardiff University - Immutep announces a License Agreement with Cardiff University granting the Company exclusive rights to develop and commercialise anti-LAG-3 small molecules. A number of promising compounds that block LAG-3, an immune checkpoint known to reduce the immune system's response to fight cancer, have been identified under Immutep's collaboration with the world-leading scientists at Cardiff University. Led by Professor Andrew Godkin of Cardiff University, Professor Andrea Brancale, and Dr Frederic Triebel, Immutep CSO, the compounds were identified by chemical library screening, molecular modelling and synthetic chemistry. A joint patent application has been filed by Immutep S.A.S. and University College Cardiff Consultants Limited to protect the new intellectual property. The License Agreement builds on Immutep's collaboration with Cardiff University which commenced in 2019. University College Cardiff Consultants Limited will receive an upfront payment of GBP 25,000 and a milestone payment upon first commercial sale of a licensed product, and is eligible to receive low single-digit sales based royalties.

08:17 EDT Teva's agreement with the ITA has no impact on 2024 financial outlook - The company's agreement with the Israel Tax Authority, ITA, has no impact on Teva's 2024 financial outlook, which the Company reaffirms.

08:15 EDT Tonix Pharmaceuticals presents vaccine platform data at Vaccine Congress 2024 - Tonix Pharmaceuticals announced data presented at an oral Keynote Talk at the Vaccine Congress 2024 held June 24-25, 2024 in Prague, Czech Republic. The presentation titled, "A New Live Virus, One Dose Vaccine Platform for Mpox, Smallpox and COVID-19", detailed the Company's vaccine platform, including TNX-801 vaccine for preventing mpox and smallpox and TNX-1800 for protecting against COVID-19. TNX-801 and TNX-1800 are live replicating attenuated vaccines based on horsepox that are believed to provide immune protection with better tolerability than modern vaccinia viruses. In the presentation, Tonix highlighted positive preclinical efficacy data, demonstrating that TNX-801 protected non-human primates against lethal challenge with intratracheal Clade 1 monkeypox virus. After a single dose vaccination, TNX-801 prevented clinical disease and lesions and also decreased shedding in the mouth and lungs of non-human primates. These findings are consistent with mucosal immunity and suggest the ability to block forward transmission, similar to Dr. Edward Jenner's vaccinia vaccine, which eradicated smallpox and kept mpox out of the human population. The presentation noted that the global mpox outbreak, which commenced in 2022, has affected over 90,000 persons in countries where mpox had previously not been endemic, including Europe and the US. The spread of Clade IIb strain mpox in 2022 underscores the pandemic potential of mpox. Unlike Clade IIb mpox, the Clade I strain of mpox remains restricted to several Central African countries, including the Democratic Republic of the Congo, where it is currently endemic. Clade I mpox is typically associated with higher case fatality rates than Clade IIb mpox. According to the U.S. Centers for Disease Control and Prevention, and other experts, there is a significant risk that the deadlier Clade I strain may appear in the U.S. Further, the presentation noted that the Bipartisan Commission on Biodefense recently highlighted the renewed dual threats of both a more virulent mpox epidemic as well as smallpox re-introduction from lab accidents or bad actors, while the National Academies of Science, in its review of smallpox preparedness, highlighted the need for new single dose vaccines against smallpox. The keynote presentation also included preclinical data for TNX-1800, demonstrating immunity and tolerability. TNX-1800 was selected by the NIH's Project NextGen for inclusion in clinical trials as part of a select group of next generation COVID-19 vaccine candidates with the intent to identify promising vaccine platforms. NIH plans to conduct a Phase 1 trial and cover the full cost, while Tonix provides the vaccine candidate.

08:14 EDT Organigram announces strategic investment in Sanity Group - Organigram announces its first significant strategic investment aimed at expanding its presence in the European cannabis market. Using proceeds from its Jupiter strategic investment pool, the Company has agreed to invest EUR 14 million initially comprised of EUR 11.5 million via an unsecured convertible note and EUR 2.5 million to purchase equity interests from existing Sanity Group founders and shareholders providing the Company with a minority stake in Berlin-based cannabis company Sanity Group GmbH. In addition, the Company may advance another EUR 3 million as a second tranche of the unsecured convertible note for future opportunities to be pursued by Sanity subject to the satisfaction of certain conditions. Organigram is also now entitled to appoint a representative to Sanity Group's Board of Directors.

12:13 EDT Osisko Gold says heap leach pad at Eagle Gold Mine experiences failure - Osisko Gold Royalties (OR) notes that its operating partner, Victoria Gold Corp. (VITFF), announced yesterday that the heap leach pad at its Eagle Gold Mine in the Yukon Territory experienced a failure. Eagle operations have been temporarily suspended while Victoria continues to assess the situation. At this early stage, it has been confirmed by Victoria that there has been some damage to infrastructure and a portion of the failure has left containment. There have been no injuries to personnel associated with the incident. Osisko is monitoring the situation closely and plans to maintain an open line of communication with Victoria as more information becomes available. Osisko holds a 5% NSR royalty on Eagle until 97,500 ounces of gold have been delivered and a 3% NSR royalty thereafter. Osisko's royalty covers the entire Dublin Gulch property including the reserves on the Eagle and Olive ore deposits and all of the exploration targets being most actively pursued by Victoria.

08:11 EDT Digimarc, Wipak partner to enhance sustainability profitability - Digimarc Corporation and Wipak announced a strategic partnership to help retailers and global brands embrace an eco-friendly strategy to product packaging. By combining Digimarc digital watermarks and Wipak's printed film technology, the companies help food, medical device, and pharmaceutical companies achieve sustainability and profitability goals through innovative packaging designed to advance the fight against plastic pollution and speed the path to net zero.

08:10 EDT Lightbridge welcomes passage of the ADVANCE Act - Lightbridge Corporation applauds the passage of the ADVANCE Act, or the Accelerating Deployment of Versatile, Advanced Nuclear for Clean Energy Act, which aims to accelerate the deployment of advanced nuclear energy in the United States. Earlier this year, the U.S. House of Representatives passed the bill on a 365-36 vote, and the U.S. Senate overwhelmingly voted 88-2 to approve the legislation. The ADVANCE Act focuses on streamlining the regulatory process at the Nuclear Regulatory Commission, supporting the development and deployment of new nuclear technologies, and strengthening the domestic nuclear supply chain. Seth Grae, President & CEO of Lightbridge Corporation, commented, "We are thrilled to see the ADVANCE Act pass with such overwhelming support in both the House and the Senate. While the Act does not remove all hurdles facing deployment of advanced nuclear technologies, this landmark legislation marks a significant step forward for the nuclear industry and reinforces the critical role of advanced nuclear technologies in our clean energy future. By streamlining regulatory processes, supporting the development of innovative nuclear technologies, and strengthening the domestic supply chain, the ADVANCE Act paves the way for a more financially sustainable and competitive nuclear energy landscape in the United States."

08:09 EDT Target announces return of Target Circle Week July 7-13 - Target announced that its biggest sale of the season, Target Circle Week, is returning July 7-13, featuring savings on summer and back-to-school essentials. The retailer will deliver more deals for members of Target Circle, its free-to-join loyalty program, including deep discounts, personalized Target Circle bonuses to put toward top summer finds, hot prices on everyday items and early savings on back-to-school and college essentials.

08:09 EDT electroCore announces commercial launch of TAC-STIM - electroCore announces the Commercial Off the Shelf COTS availability of the next generation TAC-STIM a non-invasive vagus nerve stimulator nVNS designed in partnership with the US military to enhance human performance exclusively for active-duty military use.TAC-STIM is a cutting-edge device that can accelerate learning and improve mood and cognitive performance. TAC-STIM is a portable, easy-to-use tool that leverages electroCore's patented technology to deliver precise and effective vagus nerve stimulation, helping war fighters and operators learn new tasks, increase readiness and mitigate fatigue across a range of high-pressure operational environments. TAC-STIM was originally developed in close collaboration with the 711th Human Performance Wing at the Air Force Research Laboratory AFRL, Wright-Patterson AFB, OH, as part of the United States Department of Defense Biotech Optimized for Operational Solutions and Tactics BOOS program. Independent testing by AFRL and Air Force Special Operations Command consistently demonstrated its capabilities across a range of operational settings. electroCore continues to participate in collaborative research to further enhance TAC-STIMs operational utility and showcase how TAC-STIM can enhance performance, reduce fatigue, and accelerate training without adverse effects.

08:09 EDT Bit Digital awarded GPU contract expansion to $275M - Bit Digital has finalized an agreement to supply an existing customer with an additional 2,048 GPUs over a three-year term commencing upon deployment. With this agreement, the company will supply this customer with a total of 4,096 GPUs for the respective three-year periods, amounting to total revenue of approximately $275M, or $92M on an annualized basis. To fulfill the contract, the company has placed a purchase order for 256 servers manufactured by Dell Technologies, an authorized Nvidia OEM, that are equipped with 2,048 Nvidia HGX H100 GPUs along with related equipment, expected to be delivered to the company during July. The servers will be deployed in Iceland at the datacenter where the company's existing AI servers are located and are expected to begin generating revenue in August. The company intends to finance the deal with a mixture of cash and digital assets on the balance sheet. Bit Digital has elected to enter into a sale-leaseback agreement with a third-party entity for 1,024 GPUs which will reduce the company's capital outlay commensurately. Additionally, the company continues to evaluate debt financing options that would allow the company to retroactively finance its hardware assets.

08:06 EDT Rigel Pharmaceuticals announces 1-for-10 reverse stock split - Rigel Pharmaceuticals announced that it will effect a reverse stock split of its issued and outstanding shares of common stock at a ratio of 1-for-10, effective at 12:01 a.m. Eastern Time on Thursday, June 27, 2024. The company's common stock will begin trading on a post-split basis on The Nasdaq Global Select Market under the same symbol when the market opens on Thursday, June 27, 2024, with the new CUSIP number 766559702.

08:06 EDT Heritage Financial announces CEO succession plan - Heritage Financial has named Bryan McDonald to succeed Jeffrey Deuel as President and CEO of Heritage Bank and President of Heritage Financial Corporation, effective July 1. McDonald has held the titles of President and COO of Heritage Bank since 2018. Deuel, who has served as CEO of Heritage Bank since 2018 and as President and CEO of Heritage Financial Corporation since 2019, will remain CEO of Heritage Financial Corporation until May 6, 2025, at which time he will take on an advisory role assisting the CEO and the company's board of directors. Deuel will work closely with Mr. McDonald during the transition. McDonald also currently serves as a director on the Washington Bankers Association Board and as a member of the American Bankers Association Government Relations Council.

08:05 EDT Axon says United States Marshals deploying TASER 10 - Axon announced that the United States Marshals Service has deployed Axon's next-gen less-lethal energy weapon, TASER 10. The USMS will also be piloting Axon's VR Training solution to support the deployment of TASER 10 and to provide more affordable and accessible training across a variety of immersive real-world scenarios.

08:04 EDT Enveric Biosciences prioritizes development of EB-003 - Enveric Biosciences announced the Company is prioritizing the development of EB-003, its first-in-class approach to address difficult-to-treat mental health disorders. Enveric is currently advancing pre-clinical development activities for EB-003 and targeting a Pre-IND meeting with the U.S. Food and Drug Administration, FDA, for early 2025. "EB-003 has the potential to be a breakthrough neuroplastogen drug candidate that offers the ability to treat resistant mental health disorders without the hallucinogenic effect typically associated with psychedelic-based molecules," said Joseph Tucker, Ph.D., Director and CEO of Enveric. "Minimizing the hallucinatory effect is vital for the clinical development of EB-003 since it will allow for truly blinded placebo-controlled clinical trials and eliminate the need for co-administration of psychotherapy. In addition, minimizing the hallucinatory effect will enable the administration of such therapies in an outpatient setting, and support a more widespread acceptance for psychedelic-inspired drugs."

08:04 EDT Lipocine's LPCN 1154 meets bioequivalence with IV Brexanolone in pivotal study - Lipocine announced positive topline study results demonstrating bioequivalence of LPCN 1154 to IV brexanolone in an NDA enabling pivotal pharmacokinetic study. Lipocine is developing LPCN 1154, oral brexanolone, for the treatment of postpartum depression, or PPD. The FDA has agreed with Lipocine's proposal for a 505(b)(2) NDA filing based on a single pivotal PK bridging study comparing exposure of LPCN 1154 with the approved IV infusion of brexanolone. Lipocine is targeting NDA submission by the end of Q4. The study was an open label, crossover study in 24 healthy postmenopausal women utilizing the "to be marketed" formulation and oral dosing regimen of LPCN 1154 and the commercial IV brexanolone formulation using the approved high dose infusion regimen. LPCN 1154 and IV90 brexanolone were bioequivalent based on GMRs and 90% CIs for Cmax, AUC0-, and AUC0-t meeting established criteria. Ctrough of LPCN 1154 geometric mean was higher than the trough of IV brexanolone. LPCN 1154 treatment was well tolerated with no sedation nor somnolence events observed.

12:02 EDT Stingray Group launches several FAST channels on Roku Channel - Stingray (STGYF) announced the launch of several FAST channels on The Roku Channel (ROKU), expanding its offerings in both the United States and Canada. This exciting development includes the debut of TikTok Radio on The Roku Channel, as well as the introduction of Qello Concerts and two exclusive Stingray Music audio channels, Classic Rock and Greatest Hits, in Canada.

07:57 EDT Mynaric'a CONDOR Mk3 terminal selected by ReOrbit for upcoming mission - Mynaric has been selected by ReOrbit to supply its CONDOR Mk3 terminal for its upcoming mission UKKO, aimed at demonstrating secure space-to-space and space-to-ground communication for Earth Observation.

07:53 EDT SolarEdge says may fail to collect $11.4M from bankrupt customer - SolarEdge Technologies said last night that it intends to disclose today to certain investors that PM&M Electric, a customer that owes the company approximately $11.4M under a secured promissory note recently filed for Chapter 7 bankruptcy. "While the Company is closely monitoring the proceedings, it cannot guarantee the outcome of the proceedings and may fail to collect the amounts due to the Company or collect such amounts only after significant delay," SolarEdge added.

07:47 EDT Wave Life Sciences announces data from Phase 1b/2a SELECT-HD trial for HD - Wave Life Sciences announced positive results from its Phase 1b/2a SELECT-HD clinical trial of WVE-003, which is being developed as a potential disease modifying therapeutic for Huntington's disease HD . WVE-003 is a first-in-class, allele-selective antisense oligonucleotide ASO designed to lower mutant huntingtin mHTT protein and preserve healthy, wild-type huntingtin wtHTT protein. "We are very proud to have demonstrated mHTT lowering of 46%, with preservation of wtHTT, and are encouraged to see these reductions in mHTT significantly correlating with a slowing in caudate atrophy after just 28 weeks. These results represent a significant achievement for Wave, for the oligonucleotide field, and most importantly, for the HD community," said Anne-Marie Li-Kwai-Cheung, MChem, MTOPRA, RAPS, Chief Development Officer at Wave Life Sciences. "Alongside the HD community, we have been working diligently to establish caudate volume as a biomarker for clinical development due to its association with clinical outcomes. We believe these strong data compel a case for accelerated approval for WVE-003, which we plan to discuss with regulators. We would like to express our immense gratitude to the HD community, the study participants, their families, and study site staff for their trust, support, and engagement that have helped us reach this important milestone."

07:38 EDT Zapata AI, KPMG UK complete client project to streamline compliance models - Zapata Computing Holdings and KPMG UK recently completed a client project to streamline the compliance models of a leading global insurance firm. The project aimed to transform the client's risk, operations, and compliance modeling by leveraging Zapata's analytics, optimization, and generative AI capabilities. KPMG's actuaries, working with Zapata's data engineers, converted one of the client's compliance models, comprised of tens of millions of inputs, and built an optimized solution with innovative algorithms. This new approach reduced the compute time it would have taken for these models by more than 1,000x, while maintaining accuracy and enabling the client to meet compliance requirements. Previously, the client had been submitting approximations instead of actual finished calculations.

07:35 EDT FTI Consulting launches cross-segment digital offering - FTI Consulting announced the launch of a cross-segment digital offering that leverages the full scope of FTI Consulting's deep industry expertise across the digital landscape. Individual FTI Consulting business segments have long been at the forefront of leveraging digital tools and technologies such as machine learning, artificial intelligence and advanced data and analytics to deliver efficient, defensible and bespoke client solutions. This cross-segment offering integrates these approaches to help clients attack the new, cross-cutting wave of risks and opportunities they face, from historical to emerging technologies

07:35 EDT Unicycive Therapeutics achieves study objective in OLC clinical trial - Unicycive Therapeutics announced results from the Oxylanthanum Carbonate UNI-OLC-201 pivotal clinical trial with regard to both safety and tolerability endpoints. OLC is a next-generation lanthanum-based phosphate binding agent utilizing proprietary nanoparticle technology being developed for the treatment of hyperphosphatemia in patients with chronic kidney disease. The study established promising tolerability of OLC at clinically effective doses in CKD patients on hemodialysis. In terms of tolerability, OLC had a low rate of discontinuation due to adverse events with only 5/86 patients discontinuing from the Study. Of the 5 discontinuations, 3 were treatment-related and 2 were not related to treatment. Importantly, the Company believes the low discontinuation rate for OLC compares favorably to a discontinuation rate due to AEs of 14% for Fosrenol from its U.S. Food and Drug Administration-approved Package Insert. The primary endpoint was defined as the rate of discontinuations due to treatment-related AEs leading to discontinuation in the maintenance period. In the UNI-OLC-201 trial, there was only 1 discontinuation due to a treatment-related AE in the Evaluable Population, a rate of 1.4%. In the full Safety Population, a total of 3 patients discontinued due to treatment-related AEs, a rate of 3.5%. The secondary endpoint assessing safety was also favorable as most treatment-related AEs were mild to moderate in severity and there were no treatment-related serious adverse events reported in the Safety Population. The treatment-related AEs reported in greater than or equal to5% of patients were diarrhea and vomiting which also compares favorably to Fosrenol and other phosphate binders on the market. While the study was not designed to evaluate efficacy, the trial enrolled patients on stable doses of approved hyperphosphatemia medications. At baseline approximately 59% of patients had phosphate levels less than or equal to5.5 mg/dL, the level recommended by KDOQI guidelines. After washout from the prior phosphate binders, 90% of patients were able to achieve phosphate levels less than or equal to5.5ng/dL at the end of titration with OLC.

07:33 EDT Nuvei secures Retail Services Category II License from Central Bank of the UAE - Nuvei announced that it has secured an in-principle approval for a Retail Services Category II License from the Central Bank of the UAE, representing an important strategic expansion into the United Arab Emirates and fortifying its global presence and commitment to the Middle East and North Africa region. The UAE is a crucial market for Nuvei's global customers due to its rapidly growing eCommerce sector, which is projected to surpass $10B in revenue by 2029 with an annual growth rate of approximately 9%. The Retail Services Category II License enables Nuvei to offer its comprehensive suite of payments technology to businesses operating in the thriving UAE market, including direct local acquiring, payment aggregation services, and domestic and cross-border fund transfers. Through direct local acquiring, Nuvei gains greater control over the payment life cycle, ensuring further optimized payment acceptance rates and lower processing costs for its customers. Nuvei already has a strong commercial presence and existing high-profile partnerships in the region. This expansion across the MENA region reaffirms Nuvei's commitment to supporting its customers' growth both locally and internationally.

07:32 EDT Amesite announces AI-powered documentation tool on NurseMagic app - Amesite announced that its NurseMagic app now has the capability to create nursing notes which are required, for professionals ranging from CNAs and LPNs to APRN-CNPs and NPs. Notes can be created in various formats including SOAP, PIE and DAR, speeding up the creation of required patient record documentation for all nurses. The app has experienced rapid adoption by nurses following its release to the general public, and utilizes Amesite's proprietary technology to provide useful information and assistance in real time, targeting over 5.2 million nurses.

07:31 EDT Honda selects BuyCo, FourKites to digitize, drive efficiency - Honda's divisions of Motorcycle and Power Products Operations has strategically selected BuyCo and leading real-time supply chain visibility provider FourKites to streamline their container shipping operations. With a focus on boosting efficiency and enhancing visibility, Honda's collaboration with these industry-leading technology providers marks a significant step toward advancing their supply chain.

11:29 EDT Riot withdraws previous proposal to acquire Bitfarms for $2.30 per share - Yesterday, in addition to Riot Platforms (RIOT) announcing that it had requisitioned a special meeting of Bitfarms (BITF) shareholders to reconstitute the Bitfarms board of directors, the company also announced that Riot has informed the Bitfarms board that it has formally withdrawn its previous proposal to acquire all Bitfarms common shares at a price of $2.30 per share and "stands ready to engage and negotiate with a reconstituted Bitfarms Board to pursue a mutually beneficial combination of Bitfarms and Riot." Riot stated: "Riot continues to believe that a combination of Bitfarms and Riot will create the premier and largest publicly listed Bitcoin miner globally, with geographically diversified operations well-positioned for long-term growth. Riot remains completely committed to pursuing a transaction with Bitfarms. However, it is clear that engaging with the incumbent Bitfarms Board on a potential combination is just not possible."

07:27 EDT Target Global announces postponement of Extraordinary General Meeting - Target Global Acquisition I Corp. announced its Extraordinary General Meeting of shareholders, which was originally scheduled for June 26, 2024, has been postponed to 12:00 p.m. Eastern Time, on Monday, July 1, 2024. The Postponed Extraordinary General Meeting will be held at the offices of Orrick, Herrington & Sutcliffe LLP, located at 51 West 52nd Street, New York, New York 10019. The record date remains the close of business, Eastern Time, on May 22, 2024. At the Postponed Extraordinary General Meeting, shareholders will be asked to vote on proposals to further amend the Company's Amended and Restated Memorandum and Articles of Association to eliminate the requirement to make monthly cash deposits to the Trust Account in order to extend the date by which the Company has to consummate an initial business combination from July 8, 2024 to December 9, 2024 and to allow the Company, without another shareholder vote, to elect to further extend the Termination Date, if the Company has by the Articles Extension Date entered into a letter of intent or definitive binding agreement to consummate a Business Combination, on a monthly basis for up to six times by an additional one month each time after the Articles Extension Date, by resolution of the Company's board of directors, and upon one calendar days' advance notice prior to the applicable Termination Date, until June 9, 2025, unless the closing of a Business Combination shall have occurred prior thereto; to amend that certain Investment Management Trust Agreement, dated December 8, 2021 by and between the Company and Continental Stock Transfer & Trust Company, a New York corporation, as trustee, to change the date on which Continental must commence liquidation of the trust account established in connection with the Company's initial public offering to the earliest of the Company's completion of a Business Combination; the Articles Extension Date; and the Additional Articles Extension Date; to re-appoint each of Mr. Lars Hinrichs and Ms. Sigal Regev as Class II directors on the Company's board of directors; and to ratify the selection by the Company's audit committee of Marcum LLP as the Company's independent registered public accounting firm for the Company's fiscal year ending December 31, 2024. The Proposals are described in detail in the definitive proxy statement related to the Extraordinary General Meeting filed by the Company with the Securities and Exchange Commission on June 17, 2024. As a result of this change, the Company has extended the deadline for holders of its Class A ordinary shares to submit their publicly held shares for redemption to 5:00 p.m. Eastern Time on Thursday, June 27, 2024.

07:23 EDT O-I Glass, GridBeyond to establish battery storage system in Alloa, UK - O-I Glass and GridBeyond plan to implement a battery storage solution at O-I's Alloa, UK facility. The innovative 8MW battery system and supporting energy management system leverages artificial intelligence to significantly enhance energy efficiency, resilience and sustainability By strategically charging and discharging the battery based on grid conditions, GridBeyond's AI-powered system helps to stabilize the local electricity grid during peak periods, increases O-I's resilience against brownouts, and improves the grid's efficiency and sustainability. It allows charging during times of high renewable energy availability and discharging energy to the site at peak hours of demand. With this approach, O-I is projected to conserve up to 240 tons of CO2 emissions annually at the Alloa facility once the project is operational.

07:20 EDT Constellation Software announces launch of Omegro organization - The company announced the official launch of Omegro, a new, global organization bringing together businesses from Volaris, an operating group of Constellation Software, that support customers across all aspects of the supply chain and supporting eco-system. Omegro's businesses offer a wide range of software applications such as warehousing & inventory control, ERP & CRM, fleet & logistics management, asset maintenance and process automation. Kevin Bradley and Troy O'Connor have been named Co-CEOs. Omegro is home to more than 30 business units representing over 15,000 customers, 2,000 employees, operating from 40 offices and serves customers in more than 70 countries around the world. Today's launch of Omegro, brings these businesses together under a global values-based banner, with a people-first focus to provide a permanent and safe home for software companies seeking to continue their legacy and provide long-term sustainable growth for their people and their businesses. Omegro's businesses maintain their brands and continue to service customers with the support of a larger organization with Omegro. Businesses can access Omegro's best practices, industry leadership and global presence. Omegro is made up of Adapt IT, Akuiteo, AMS Life Insurance and Workforce Management, CentroAssist, CPR Vision, Drams, Evolis, FIVE x 5, Gaina, Helm, Holocentric Enterprise and Holocentric Federal Government, IDEA, Incom, Infoview, Lutra, Shipnet, Smartrak, Spectec and Spectec Cruise, ValuePro and Worldwide Chain Stores.

07:18 EDT Rose LifeScience announces quality upgrade to Pure Laine Big Pleasures - ROSE LifeScience announced a significant upgrade to its top-selling 28g dried-flower product Big Pleasures by Pure Laine. ROSE is adding Oxygen Absorbers to each package to improve product quality. Oxygen Absorbers, new to the cannabis industry, are designed to optimize packaging environments by significantly reducing oxygen levels. Big Pleasures by Pure Laine is a 28g rotating dried-flower product available in select retail stores across Canada, and was the top selling SKU in Canada in May. Updated packaging with Oxygen Absorbers is expected to roll out in early July. Rose LifeScience is majority owned by Village Farms International.

07:11 EDT BioXcel Therapeutics announces results from PMR study of IGALMI - BioXcel Therapeutics announced topline results from a post-marketing requirement study of IGALMI sublingual film that demonstrated no evidence of tachyphylaxis, tolerance, or withdrawal with the 180 mcg dose after seven days of PRN (as-needed) treatment. In the single-arm, open-label study, 28 inpatient adults with frequent episodes of agitation associated with bipolar disorders or schizophrenia self-administered 180 mcg dose of IGALMI as needed over seven days. A total of 83 episodes were treated. Efficacy Measurements: although this PMR study was not statistically powered to evaluate repeat-dose efficacy, changes in agitation were assessed through the Positive and Negative Syndrome Scale-Excitatory Component Score and the Clinical Global Impressions - Improvement Scale, the same measures as used in previous Phase 3 studies. Mean PEC score reduction was observed following all doses of IGALMI administered as needed over the treatment period. All patients showed improvement in agitation symptoms as assessed by the CGI-I Scale for all doses administered as needed over the treatment period Prior to treatment with IGALMI, most patients exhibited mild to moderate agitation as assessed by the Agitation Calmness Evaluation Scale. ACES scores post-dose revealed a marked calming effect with no patient experiencing unarousable somnolence. In addition, no withdrawal or rebound phenomena were observed. Safety and Tolerability Results: The 180 mcg dose of IGALMI was generally well tolerated and showed favorable safety results in treating patients with frequent episodes of agitation. There were no discontinuations due to adverse events. No serious adverse events were reported.

11:09 EDT Aurora Innovation, Uber Freight launch Premier Autonomy program - Uber Freight (UBER) and Aurora Innovation (AUR) are launching Premier Autonomy, a new program providing early access to over 1 billion of Aurora's driverless miles to Uber Freight carriers through 2030. The program is the latest in their longstanding partnership to integrate and deploy autonomous trucks on the Uber Freight network to enable carriers of all sizes to improve utilization and enhance business efficiency through autonomous technology. Additionally, Uber Freight will be one of Aurora's first customers on its Dallas-to-Houston freight route, with driverless hauls for shippers expected at the end of 2024.

07:06 EDT NFI Group's Alexander Dennis receives order for 244 buses from Stagecoach - NFI Group subsidiary Alexander Dennis announced that it has taken a firm order from transport group Stagecoach for 244 of its next-generation zero-emission buses. Stagecoach supported numerous local authorities across England in successful bids to the second round of the UK Government's Zero-Emission Regional Bus Areas scheme. Following the funding award, the group has now been able to place the largest single order of Alexander Dennis' zero-emission buses to date.

07:06 EDT ImmunoPrecise Antibodies, PGxAI announce strategic collaboration - ImmunoPrecise Antibodies announced that its subsidiary, BioStrand, is collaborating with PGxAI to leverage BioStrand's patented Foundation AI Model, LENSai. This collaboration advances the precision medicine field of pharmacogenomics and supports LENSai Application Programming Interface commercial rollout through expanding LENSai features and market reach. "The work we've begun with PGxAI marks a significant application of LENSai to a critical real-world challenge, enabling the development of a unique pharmacogenomics AI model," said Dr. Jennifer Bath, President, and CEO of IPA. "With more genomic data and new pharmacogenetic insights, more advanced methods are urgently needed to analyze and predict treatment responses and adverse drug reactions. We believe that LENSai offers a potentially groundbreaking approach to creating an adaptive AI model that is designed to predict individual patient responses to both existing and new drugs."

07:05 EDT GreenTree Hospitality reaffirms 2024 hotel business revenue growth view 7%-12% - The company said, "Based on our performance in the first five months of this year, we maintain our previous revenue guidance for the hotel business, that we expect to grow 7% to 12% year-over-year. We are withdrawing our guidance for the restaurant business given the significant revenue unpredictability resulting from its strategic repositioning."

07:04 EDT Tesla recalling over 11,000 2024 Cybertrucks to fix problems with trim pieces - Tesla is recalling 11,383 model year 2024 Cybertruck vehicles manufactured from November 13, 2023, to May 26, 2024, the NHTSA says in documents posted to its website. The Cybertruck is equipped with a cosmetic applique along the exterior of the trunk bed trim, known as the sail applique, which is affixed to the vehicle with adhesive. On affected vehicles, the sail applique or adhesion may not have been installed according to specification, which may cause the sail applique to become loose or separate from the vehicle. If the applique separates from the vehicle while in drive, it could create a road hazard for following motorists and increase their risk of injury or a collision, the NHTSA said. As of June 12, 2024, Tesla is not aware of any collisions, injuries, or deaths relating to this condition. Reference Link

07:02 EDT Clear Secure announces seven new locations - Clear Secure continues to expand locations to enroll and renew consumers in the Trusted Traveler program by opening 7 new locations. CLEAR now has 27 TSA PreCheck enrollment locations open across the U.S. The launch of the enrollment location at these 7 airports represents the ongoing expansion of CLEAR's national TSA PreCheck enrollment footprint. Throughout 2024, CLEAR will continue delivering convenience to consumers by launching additional locations and extended hours of operation for enrollment and renewals. The 7 new locations include: Hartsfield-Jackson Atlanta International Airport (ATL); Austin-Bergstrom International Airport (AUS); Denver International Airport (DEN); Detroit Metropolitan Wayne County Airport (DTW); Rhode Island T.F. Green International Airport (PVD); San Jose Mineta International Airport (SJC); Luis Munoz Marin International Airport (SJU).

07:02 EDT 908 Devices appoints Leonhart to Board of Directors - 908 Devices has appointed Michele Leonhart, the former Administrator of the United States Drug Enforcement Administration, DEA, to serve on its Board of Directors effective immediately. Leonhart brings a deep understanding of our customers in law enforcement and adjacent markets. Her 34-year career in the DEA encompassed various positions with increasing levels of responsibility. Leonhart retired from the DEA in 2015 and has served on the Board of Directors of the non-profit D.A.R.E America / D.A.R.E. International since 2015, and as its Board Chair since 2018.

06:58 EDT Ionis Pharmaceuticals announces FDA acceptance of olezarsen NDA - Ionis Pharmaceuticals announced that the U.S. Food and Drug Administration has accepted for Priority Review the New Drug Application for olezarsen, an investigational RNA-targeted medicine for the treatment of adults with familial chylomicronemia syndrome. The FDA has set an action date of December 19, 2024 and indicated they are not currently planning an advisory committee meeting for olezarsen. he application to the FDA was based on positive results from Balance, a global, multicenter, randomized, double-blind, placebo-controlled Phase 3 study. The study results were presented at the 2024 American College of Cardiology Annual Meeting and published simultaneously in The New England Journal of Medicine. The U.S. FDA granted olezarsen Fast Track designation for the treatment of FCS in January 2023, as well as Orphan Drug designation and Breakthrough Therapy designation in February 2024. Ionis is planning additional regulatory filings for the treatment of FCS in the European Union this year.

06:50 EDT International Game awarded contract by Ohio Lottery Commission - International Game Technology has won a competitive bidding process to provide the Ohio Lottery Commission's video lottery terminal central monitoring system, with a contract effective May 31, 2024 through June 30, 2033. The agreement includes an option for Ohio to renew the contract for up to two additional one-year terms. Under the terms of the agreement, IGT will provide its advanced Intelligent central monitoring system hardware and software, with continual monitoring and support for more than 10,000 video lottery terminal machines distributed throughout seven racinos across Ohio: Belterra Park Cincinnati, Eldorado Scioto Downs, Jack Thistledown Racino, Hollywood Gaming Dayton Raceway, Hollywood Gaming Mahoning Valley Race Course, MGM Northfield Park and Miami Valley Gaming.

06:35 EDT AstraZeneca's Imfinzi demonstrated statistically significant improvement - Positive high-level results from the NIAGARA Phase III trial showed AstraZeneca's Imfinzi in combination with chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of event-free survival and the key secondary endpoint of overall survival versus neoadjuvant chemotherapy for patients with muscle-invasive bladder cancer. Imfinzi was generally well-tolerated and no new safety concerns were observed in either the neoadjuvant or adjuvant setting. The safety profile of Imfinzi and neoadjuvant chemotherapy was consistent with the known profile of the individual medicines. The addition of Imfinzi did not increase the discontinuation rate due to adverse events and did not compromise patients' ability to complete surgery compared to neoadjuvant chemotherapy alone.

06:33 EDT Target names Christina Hennington chief strategy, growth officer, Rick Gomez CCO - Target Corporation announced it has named Christina Hennington, currently chief growth officer, as chief strategy and growth officer, and Rick Gomez, currently chief food, essentials and beauty officer, as chief commercial officer, overseeing Target's merchandising business, both effective July 7. Lisa Roath, Target's chief marketing officer, will take on the role of chief merchandising officer of food, essentials and beauty in early 2025. The company is initiating an external search for its next chief marketing officer and, until a successor is named, Roath will remain in full capacity as chief marketing officer. As chief strategy and growth officer, Hennington will work closely with Cornell, Fiddelke and the rest of Target's leadership team to build on the retailer's roadmap for growth, ensuring the strategy remains relevant and differentiated as the company plans into its next growth horizon. Hennington and her team also will play a critical role in supporting the organization as it continues to evolve and modernize how it operates, including harnessing the role of technology and generative AI to enhance the working and shopping experience at Target. Additionally, Hennington will be responsible for further strengthening relationships with Target's strategic partners and identifying new partnerships that will differentiate and drive the retailer's business. Hennington will continue to report to Cornell. As chief commercial officer, Gomez will have full oversight of Target's merchandising business, including its apparel and accessories, home, hardlines, food, essentials and beauty product categories, owned brand sourcing and design and merchandising planning and capabilities. Under Gomez's leadership, Target will continue to lean into its well-established authority in merchandising, flexing its multicategory assortment to meet the evolving wants and needs of current and prospective guests with speed and agility across its commercial businesses. Gomez will report to Cornell. Early next year, Roath will take on the role of the retailer's chief merchandising officer of food, essentials and beauty. In that role, Roath will report to Gomez. Until that time, Roath will remain in full capacity as Target's chief marketing officer and will continue to report to Cara Sylvester, Target's chief guest experience officer.

06:32 EDT BJ's Wholesale to open new clubs in New Jersey, North Carolina in 2025 - BJ's Wholesale announced the locations of its newest clubs, set to open in early 2025. The clubs in Hanover Township and Southern Pines will mark the retailer's 25th club in New Jersey and 10th in North Carolina. The company announced earlier this year eight new clubs opening across the Southeast, Midwest and Northeast, as well as expansion into its 21st state with an opening in Louisville, KY in early 2025.

06:18 EDT TriNet announces series of new product enhancements, capabilities - TriNet announced a series of new product enhancements, capabilities and strategic partners designed to meet the needs of its customers in today's ever-evolving business environment. These announcements were made today in Chicago at the Society for Human Resource Management Annual Conference and Expo 2024. TriNet's announced marketplace and product enhancements include the following: Marketplace: Through TriNet's thoughtfully curated network of solutions for SMBs, customers can confidently and conveniently find solutions to their ever-changing needs. This update will provide: A reputable network of solutions for confident decision-making, in a convenient online platform. Easily sort from a range of categories: HR, finance, talent acquisition, recruiting, global workforce, expense, security and more. Preferred pricing on a number of solutions that translates into potential cost savings for its customers. Prebuilt integrations that connect and sync data across select applications for greater security, accuracy and efficiency. Additionally, its customers can conveniently access single sign-on to select integrated apps. Global Workforce: TriNet is partnering with leading global employment platforms Oyster and Multiplier to support the international growth of its customers. The collaboration will include prebuilt integrations allowing customers to visualize and track their full workforce, US and international, from TriNet's PEO platform and with global employment platform partners. Mobile app, payroll run approval: New mobile app feature will allow administrators to review and approve payroll runs while on the go. Administrators will be able to efficiently manage the time-sensitive nature of payroll processing with a few quick taps. This new app feature will be available on TriNet PEO. Earned Wage Access: Delivered through an integration with digital banking app Clair, SMBs can now offer their employees early access to earned wages and other financial wellness services at no additional cost to the business or the employees. This offering can help businesses improve retention, increase productivity, and support their employees' financial well-being. Available now with payroll on TriNet's HR Platform.

10:07 EDT Ideaya announces first-patient-in for Phase 1 trial of IDE397 with Trodelvy - IDEAYA Biosciences (IDYA) has dosed its first patient in the IDEAYA-sponsored Phase 1 trial evaluating the combination of IDE397, IDEAYA's investigational MAT2A inhibitor, and Trodelvy, Gilead's (GILD) Trop-2 directed ADC, in patients with MTAP-deletion bladder cancer. The IDE397 and Trodelvy combination Phase 1 trial is included as an arm of an ongoing IDEAYA-sponsored clinical trial, which includes a Phase 2 expansion arm of IDE397 monotherapy in MTAP-deletion solid tumors. The global Phase 1 clinical trial will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of IDE397 in combination with Trodelvy. IDE397 is a potent and selective small molecule inhibitor targeting methionine adenosyltransferase 2 alpha in patients having solid tumors with methylthioadenosine phosphorylase deletion. Gilead's Trodelvy is currently approved in nearly 50 countries for 2L metastatic triple-negative breast cancer and in more than 30 countries for pre-treated HR+/HER2- metastatic breast cancer. In the U.S., Trodelvy has an accelerated approval for the treatment of patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and anti-PD-(L)1 therapy. Pursuant to the clinical study collaboration and supply agreement, IDEAYA and Gilead retain the commercial rights to its respective compounds, including with respect to use as a monotherapy or combination agent. IDEAYA is the study sponsor and Gilead will provide the supply of Trodelvy to IDEAYA.

10:04 EDT Castrol to invest up to $50M in Gogoro - Castrol, part of the bp group (BP), announced an investment of up to $50 million in Gogoro (GGR). In the first tranche of the investment, Castrol Holdings, an affiliate of Castrol, will invest $25 million in ordinary shares of Gogoro. This investment is expected to be followed by a second $25 million investment in the form of a convertible note, which is subject to the consummation of certain transactions by the parties in connection with their business collaboration. The first tranche investment will result in Castrol acquiring approximately 5.72% of Gogoro's outstanding ordinary shares and it will be Castrol's first step to unlock diversification opportunities beyond its core lubricants and fluids business under its new 'Onward, Upward, Forward' strategy.

10:02 EDT Halozyme: Roche's OCREVUS SC with ENHANZE receives EC approval - Halozyme Therapeutics (HALO) announced that Roche (RHHBY) received European Commission marketing authorization of OCREVUS SC co-formulated with ENHANZE, Halozyme's proprietary recombinant human hyaluronidase enzyme, rHuPH20, for the treatment of relapsing multiple sclerosis and primary progressive multiple sclerosis. OCREVUS SC is a 10-minute injection that maintains the same twice-yearly schedule as the approved IV infusion. The SC injection was designed to be administered by healthcare professionals, with the flexibility to be administered either in the clinic or in settings outside the clinic.

00:38 EDT Boeing awarded $211M U.S. Navy contract - The Boeing Co is awarded a not-to-exceed $210,941,000 ceiling-priced delivery order N00383-24-F-YY1T under previously awarded basic ordering agreement for procurement of nine various configurations of flight control surface spares used on the F/A-18E/F and E/A-18G aircrafts. The delivery order does not include an option period.

20:04 EDT Cathie Wood's ARK Investment buys 33K shares of Roku today

19:50 EDT Nikola trading halted, news pending

19:30 EDT Chemours resumes production at TiO2 site in Mexico - The Chemours Company announced that the Mexican government has lifted its prior water intake restrictions, enabling the Company to resume normal operations at its titanium dioxide manufacturing facility in Altamira, Mexico.

18:31 EDT Pool Corp. sinks 11% to $300.55 after cutting outlook

18:03 EDT Comstock Holding names Robert Demchak as new General Counsel - Comstock Holding announced the appointment of Robert Demchak to the Executive Leadership team as General Counsel and Corporate Secretary, effective June 24. Demchak brings over 25 years of experience as a real estate and capital markets attorney and as a REIT executive. His experience encompasses corporate governance, capital markets, regulatory compliance, and management of commercial real estate related transactions.

17:54 EDT Gossamer Bio CEO buys $250K in common stock - In a regulatory filing, Gossamer Bio disclosed that its CEO Faheem Hasnain bought 372K shares of common stock on June 21st in a total transaction size of $250K.

17:20 EDT Fresh2 Group plans to implement ADS ratio change - Fresh2 Group announced that it plans to change the ratio of its American depositary shares to its Class A ordinary shares from one ADS representing twenty Class A ordinary shares to one ADS representing two hundred Class A ordinary shares. The ADS ratio change is expected to become effective on or about July 10.

17:01 EDT Stran & Company receives Nasdaq notice over late 10-Q filing - Stran & Company announced that it received a written notification, dated June 21, 2024, from The Nasdaq Stock Market LLC, notifying the company that it is not in compliance with the periodic financial report filing requirement set forth in Nasdaq Listing Rule 5250(c)(1) for continued listing on The Nasdaq Capital Market tier of Nasdaq since the company has not yet filed its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2024. The company has 60 calendar days, or until August 20, 2024, to submit a plan to Nasdaq to regain compliance, and, if Nasdaq accepts the Plan, Nasdaq may grant an exception of up to 180 calendar days from the Form 10-Q's due date, or until December 16, 2024, to regain compliance. If Nasdaq does not accept the Plan, the company will have the opportunity to appeal that decision to a Nasdaq Hearings Panel. As previously announced on May 13, 2024, the company was required to dismiss BF Borgers CPA PC as the company's independent registered public accounting firm. The Company was required to engage a new independent registered public accounting firm in order to complete and file the Form 10-Q. On June 20, 2024, the company announced that it had engaged a new independent registered public accounting firm, Marcum LLP.

16:48 EDT Ascendis Pharma presents data from Phase 2 ACcomplisH Trial of TransCon CNP - Ascendis Pharma announced the oral presentation of data from its Phase 2 ACcomplisH Trial of TransCon CNP in children aged 2 to 10 years old with achondroplasia by Ravi Savarirayan, M.D., Murdoch Children's Research Center, during ICCBH 2024, the International Conference on Children's Bone Health being held in Salzburg, Austria. The data showed that patients treated for one year at the pivotal 100undefined/kg/week dose demonstrated significant improvements in well-being and physical functioning compared to placebo. These improvements could not be explained by changes in linear growth only, supporting a potential additional direct treatment effect of TransCon CNP beyond linear growth.

16:38 EDT Advantage Solutions CEO buys $111.6K in common stock - In a regulatory filing, Advantage Solutions disclosed that its CEO David Peacock bought 40K shares of common stock on June 21st in a total transaction size of $111.6K. Shares of Advantage Solutions are up 2% afterhours at $2.93.

16:36 EDT Merck KGaA discontinues Phase III TrilynX study - Merck KGaA announced the discontinuation of the Phase III randomized TrilynX study evaluating xevinapant plus chemoradiotherapy in patients with unresected locally advanced squamous cell carcinoma of the head and neck. The decision follows a pre-planned interim analysis performed by the study's Independent Data Monitoring Committee, which found that the trial would be unlikely to meet its primary objective of prolonging event-free survival. Top-line safety data were overall compatible with the chemo-radio sensitizing properties of xevinapant. The company will conduct an in-depth review of the data and will share the results in a peer-reviewed forum. LA SCCHN has proven to be a difficult-to-treat form of cancer. CRT has remained the standard of care for decades, despite multiple studies designed to improve outcomes with new treatment approaches, including multiple immunotherapy trials. "We sincerely thank the patients, caregivers and clinical investigators who participated in this trial," said Danny Bar-Zohar, Global Head of Research & Development and Chief Medical Officer for the Healthcare business sector of Merck KGaA, Darmstadt, Germany. "While we are disappointed by these results, we remain steadfast in our commitment to develop transformative medicines within our oncology portfolio for areas of high unmet need." Given the totality of the data, the company decided to also stop the Phase III clinical trial X-Ray Vision (xevinapant plus radiotherapy, compared to placebo plus radiotherapy) in patients who underwent resection of locally advanced head and neck cancer.

16:34 EDT J.M. Smucker CEO Smucker sells 10,000 common shares - In a regulatory filing, J.M. Smucker chairman, president, and CEO Mark Smucker disclosed the sale of 10,000 common shares of the company on June 21 at a price of $110.16 per share.

16:29 EDT Pool Corp. to resume trading at 4:30 pm ET - Pool Corp. shares are set to resume trading at 4:30 pm ET, with quotation scheduled to resume at 4:25 pm ET, according to Nasdaq.

16:27 EDT Mosaic: April-May potash sales revenue $371M vs. $672M last year - Previous second quarter 2024 guidance is reiterated. Potash sales volume and MOP prices at the mine are expected to be in the range 2.2-2.4M tonnes, and $210-$250 per tonne, respectively. Phosphates sales volumes and DAP prices at the plant are expected to be in the range of 1.6-1.8 million tonnes, and $530-$580 per tonne, respectively.

16:18 EDT Cohen & Steers says Raja Dakkuri to succeed Matthew Stadler as CFO - Cohen & Steers (CNS) announced that Raja Dakkuri has joined Cohen & Steers as Executive Vice President and CFO. Dakkuri succeeds Matthew Stadler, who previously notified Cohen & Steers on October 17, 2023 of his intention to retire during 2024 upon the appointment of his successor. As CFO, Dakkuri will lead the firm's financial operations, financial strategy and investor relations. He joins the firm's Executive Committee and reports to Joseph Harvey, CEO and President. Dakkuri joins Cohen & Steers from Valley National Bancorp and Bank (VLY), where he served as Chief Risk Officer.

16:11 EDT Nidar Infrastructure to go public via merger with Cartica Acquisition Corp - Nidar Infrastructure Limited and Cartica Acquisition Corp announced that they have entered into a definitive Agreement and Plan of Merger for a business combination. Nidar is India's leading data center provider for artificial intelligence and high-performance compute. Nidar provides advanced information technology infrastructure and solutions on an "as-a-Service" model to customers worldwide, including enterprises, governments, start-ups and small- and medium-sized enterprises, and hyperscalers. Nidar's offerings include colocation services, managed services and cloud services, and AI services. The pre-transaction equity value of Nidar implied by the Business Combination terms is approximately $2.75B.

16:08 EDT Orion Group awarded three contracts with total value of approximately $63M - Orion Group Holdings announced three contract awards, two in its Concrete segment and one in its Marine segment. Each of the three projects is scheduled to start in Q3 of 2024 and run for nine to twelve months.

16:08 EDT Illumina completes divestiture of Grail - Illumina (ILMN) announced the successful completion of the spin-off of Grail (GRAL). This milestone follows the company's previously announced plans to divest Grail, and Grail is now a public and independent company. Grail will begin regular way trading on Nasdaq on Tuesday, June 25 under the ticker symbol "GRAL." Illumina will continue to trade on Nasdaq under the ticker symbol "ILMN."

16:07 EDT Cleveland-Cliffs to host Senator Sherrod Brown, USW's McCall at Cleveland Works - Cleveland-Cliffs announced that Lourenco Goncalves, Chairman, President and Chief Executive Officer is hosting Senator Sherrod Brown of Ohio and leadership from the United Steelworkers, David McCall, USW International President and Donnie Blatt, Director of USW District 1, at its Cleveland Works plant in Ohio on Wednesday, June 26 for a press conference. Senator Brown's visit follows the recent bipartisan legislation introduced to stop the dramatic increase in Mexican steel imports. The Stop Mexico's Steel Surge Act reinstates the 232 tariffs on Mexican steel imports at 25 percent, for no less than a year, and gives the President of the United States the authority to impose additional quotas and tariff rate quotas on specific products if necessary. Senator Brown has led efforts pushing the current administration to take aggressive action to enforce the agreement to level the playing field for American manufacturers and workers in the steel industry, the company said. During the visit, Senator Brown will meet with Cleveland-Cliffs' CEO Lourenco Goncalves and USW International President David McCall, as well as with local union leaders and employees regarding this important trade enforcement matter.

16:06 EDT Rigel Pharmaceuticals completes transfer of GAVRETO NDA - Rigel Pharmaceuticals announced the completion of the transfer to Rigel of the New Drug Application for GAVRETO for the treatment of adult patients with metastatic rearranged during transfection fusion-positive non-small cell lung cancer as detected by a U.S. FDA approved test and adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory. GAVRETO will be commercially available from Rigel in the U.S. by prescription beginning June 27, 2024.

16:04 EDT Iron Mountain CHRO Baker-Greene sells 6,200 common shares - In a regulatory filing, Iron Mountain executive VP and chief HR officer Edward Baker-Greene disclosed the sale of 6,200 common shares of the company on June 20 at a price of $88.35 per share.

16:01 EDT Hyzon Motors announces realigning of strategic priorities - Hyzon announced that after a comprehensive review of Hyzon's business operations, Hyzon has started realigning its strategic priorities along several lines to focus on the company's core North American markets and the refuse industry. In addition to the company's previously disclosed efforts to secure capital, the company announced that it has retained PJT Partners as its financial advisor to lead the ongoing capital raise efforts including via capital markets transactions, and to explore a full range of strategic options for the company, which could potentially include a sale of the company and/or a divestiture of its Europe and Australia/New Zealand businesses and subsidiaries, amongst other alternatives. As the company explores such strategic alternatives, it will continue to focus on cost reduction efforts and managing liquidity, including a reduction in work force or other strategic transactions and/or measures. The realignment process will allow Hyzon to focus its financial resources and investments, better position its first-to-market, single stack 200kW, fuel cell technology in its zero emissions North American Class 8 and refuse truck FCEV platforms as it prepares to launch its significant large fleet trial programs on both platforms in the U.S. and Canada this summer.

14:50 EDT Bitfarms says Riot has declined to engage 'constructively' - Bitfarms (BITF) confirmed that it has received a shareholder meeting requisition from Riot Platforms (RIOT). The shareholder meeting is being requisitioned to gain control of the company's Board of Directors. Bitfarms issued the following statement: "The Bitfarms Board of Directors and management team are committed to acting in the best interests of the Company and all of its shareholders. In that regard, the Board established a Special Committee of independent directors to conduct a strategic alternatives review process to thoroughly evaluate all opportunities to maximize shareholder value. The Special Committee determined that Riot's April 22, 2024 proposal of $2.30 per share (which represents a 22% discount to Bitfarms closing price as of June 21, 2024) significantly undervalued the Company and offered to enter into a confidentiality and standstill agreement with Riot and provide additional information about the Company so that Riot could improve its proposal. Since that time, the Special Committee has repeatedly invited Riot to participate in the process, even executing the confidentiality and standstill agreement proposed by Riot. The Special Committee is disappointed that Riot declined to engage constructively and participate in the process, and instead has continued to take steps to attempt to undermine the integrity of the process and harm the interests of other Bitfarms shareholders. The Board and Special Committee remain committed to achieving the best outcome for all Bitfarms shareholders." The company remains committed to constructive engagement with all shareholders and will review the requisition and provide an update in due course. Bitfarms shareholders are not required to take action at this time.

13:32 EDT Novo Nordisk presents full results from FLOW trial of Ozempic - Novo Nordisk presented the full results from FLOW, its phase 3b kidney outcomes trial investigating the effects of once-weekly injectable semaglutide 1 mg in adults with type 2 diabetes and chronic kidney disease, or CKD, at the 84th Annual Scientific Sessions of the American Diabetes Association, or ADA. The double-blind, randomized, placebo-controlled trial, which enrolled 3,533 people with type 2 diabetes and CKD, achieved its primary endpoint, with semaglutide 1 mg demonstrating a 24% reduction in the risk of kidney disease progression and cardiovascular and kidney mortality compared to placebo. The primary outcome was major kidney disease events, a composite of onset of kidney failure, a sustained 50% or greater reduction in eGFR from baseline, or death from kidney-related or cardiovascular causes. "Treating serious comorbidities like chronic kidney disease is critical to improving treatment outcomes for people with type 2 diabetes. The results from the FLOW trial represent important data, as we look to better understand what GLP-1 treatment options could mean for this patient population. Leveraging our deep expertise in cardiometabolic science, we are proud to continue building strong clinical evidence on the strength and versatility of semaglutide to deliver results for people living with serious chronic diseases," said Anna Windle, PhD, senior vice president clinical development, Medical & Regulatory Affairs at Novo Nordisk.

13:19 EDT Digital Health Acquisition Corp trading resumes

13:08 EDT Nvidia Head of IR says leaving for 'startup CFO opportunity' - Simona Jankowski, Vice President, Head of Investor Relations & Strategic Finance at NVIDIA, stated in a LinkedIn post: "After seven amazing years, I have decided to leave NVIDIA for a startup CFO opportunity (more on that in a future post). It was not an easy decision. NVIDIA has been close to my heart for over two decades. As a newly minted equity research analyst at Goldman Sachs in 2001, my first assignment was building the NVDA financial model, and I met Jensen Huang as part of our initiation of coverage. I loved following the stock throughout the 2000s - cool product launches, rapid technology advances, supply chain trips to Taiwan, Q&As with Jensen, the birth of CUDA - these were fertile ground for many tech deep dives and (mostly good) stock calls. It helped me make my name as an analyst and I learned a lot." Reference Link

12:26 EDT Norfolk Southern says addresses FRA's safety culture assessment recommendations - Norfolk Southern Corporation said it has implemented measures to address the Federal Railroad Administration's recommendations from its 2023 Safety Culture Assessment. The Assessment, issued in August 2023, made recommendations in the areas of communications, training, trust, and going above and beyond regulatory minimums. Norfolk Southern, working with its independent safety consultant AtkinsRealis US Nuclear, developed action items in response to these recommendations. The company has successfully launched initiatives to implement all items and will monitor these actions to ensure their effectiveness. "We appreciate the strong partnership with FRA on advancing safety and are grateful for its thorough assessment of our culture and their thoughtful recommendations, all of which serve as building blocks to our goal of becoming the gold standard for safety in the industry," said Alan H. Shaw, president and CEO of Norfolk Southern. Norfolk Southern and FRA worked closely together throughout the implementation of the responsive action items. The company provided frequent updates to FRA on its progress, which included briefings by Shaw to FRA Administrator Amit Bose and his senior leadership team.

12:04 EDT ResMed falls -11.3% - ResMed is down -11.3%, or -$23.33 to $182.50.

12:02 EDT Redwire rises 15.3% - Redwire is up 15.3%, or 89c to $6.72.

12:00 EDT RXO Inc. rises 23.2% - RXO Inc. is up 23.2%, or $4.69 to $24.90.

11:10 EDT Lead Real Estate board approves special cash dividend - Lead Real Estate's Board of Directors approved a special cash dividend, payable on or about September 30, 2024, to all shareholders of record as of June 30, 2024 with an American depositary receipt record date of June 28, 2024. The dividend will be subject to shareholder approval at the Company's annual general meeting to be held in September 2024.

10:33 EDT Cadeler reports contract for installation of 72 15MW wind turbines at Inch Cape - In a regulatory filing earlier, Cadeler A/S announced the signing of a firm contract with Inch Cape Offshore Limited for the installation of 72 Vestas 15MW offshore wind turbines at Inch Cape Offshore Wind Farm. "The contract value is projected to fall within the range of EUR 114 - 130 million, with installation due to commence in the fourth quarter of 2026. This project illustrates Cadeler's commitment to expanding its partner portfolio, while strengthening and diversifying its contract backlog. Located 15 kilometres off the East Coast of Scotland in the North Sea, Inch Cape Offshore Wind Farm will generate enough energy to power the equivalent of approximately 1.6 million UK households. For the successful execution of this project, Cadeler will utilize one of its two state-of-the-art newbuild M-class installation vessels. The overall duration of the project is estimated to be around 249 days," the company stated. Mikkel Gleerup, CEO of Cadeler, said: "This contract once again illustrates the increasing demand for our new build state-of-the-art vessels and our commitment to expanding our partner portfolio, while strengthening our overall contract backlog. With the recent renewal and continuing expansion of our fleet of jack-up offshore wind installation vessels - the industry's largest - Cadeler is ready to meet the fast-growing and dynamic market demand." Reference Link

10:06 EDT Stratasys, AM Craft partner to drive growth in 3D part manufacturing - Stratasys and AM Craft are partnering to align the two companies' efforts to grow the demand for flight-certified 3D printed parts in the aviation industry. The companies signed a definitive commercial collaboration agreement, along with Stratasys' strategic investment in AM Craft. Holding an EASA Part 21G Production Organization Approval, AM Craft solves a key barrier to broader adoption of 3D printed parts in the aviation industry by delivering airworthiness certified parts to airlines, MROs, and OEMs. Additive manufacturing has strong appeal as a supply chain solution in these markets due to the long sustainment life of aircraft and the resulting challenges in forecasting and stocking replacement parts.To facilitate the partnership with Stratasys, Stratasys SVP Jeff Hemenway is joining the AM Craft board of directors. AM Craft currently produces aviation components in Europe and has demonstrated the ability to extend their Production Organization Approval to Paradigm 3D, a partner company in Dubai, UAE. Stratasys currently engages in certified aviation parts manufacturing through subsidiary Additive Flight Solutions in Singapore. In structuring this partnership, AM Craft will own and operate AFS, further extending AM Craft's production network to Southeast Asia, and add a Hamburg facility later this year. The combined network operates 13 printers under EASA 21G approval, which have produced more than 28,000 flight parts to date. A future step within the partnership will be to evaluate collaboration with US-based Stratasys Direct Manufacturing, and their substantial install base of similar equipment.

10:04 EDT Microvast, Evoy forge partnership for boat electrification - Microvast Holdings announced a strategic partnership with Evoy, a Norwegian company specializing in high-output electric motor systems for boats. The collaboration with Evoy is Microvast's debut in the electric boat segment and marks an expansion of Evoy's battery options for diverse market applications. Evoy will be integrating Microvast MV-I high-power battery packs into their leisure boat product line. The MV-I battery pack offers a range of environmental and technical benefits, such as fast responsive torque for quick acceleration.

10:03 EDT Inspire Medical falls -13.2% - Inspire Medical is down -13.2%, or -$21.45 to $141.01.

10:02 EDT Redwire rises 6.5% - Redwire is up 6.5%, or 38c to $6.21.

10:00 EDT RXO Inc. rises 14.3% - RXO Inc. is up 14.3%, or $2.88 to $23.09.

09:52 EDT Mytheresa falls -6.7% - Mytheresa is down -6.7%, or -33c to $4.60.

09:51 EDT ResMed falls -7.5% - ResMed is down -7.5%, or -$15.54 to $190.29.

09:50 EDT Inspire Medical falls -10.8% - Inspire Medical is down -10.8%, or -$17.49 to $144.97.

09:48 EDT Prudential plc rises 6.9% - Prudential plc is up 6.9%, or $1.25 to $19.26.

09:45 EDT Lead Real Estate Co Ltd (ADR) trading halted, volatility trading pause

09:41 EDT SWVL Holdings Corp trading halted, volatility trading pause

09:33 EDT TMT Acquisition merger partner eLong Power receives RMB480M purchase order - The merger partner of TMT Acquisition Corp, eLong Power Holding, announced that its wholly-owned subsidiary has signed a supply contract for energy storage systems valued at RMB480M, approximately $66M. The execution of this supply contract follows a strategic partnership agreement signed last year with a major general contractor in the Chinese energy construction industry. The contract is for a 600MWh lithium battery storage system to be installed for a municipal project in Shandong province, China, with delivery expected by October 31, 2024. The contract contains provisions for an advance payment of 30% of the total contract price 3 months prior to shipment, an additional 60% within 7 business days after product delivery and installation with the 10% balance subject to product quality assurances for a year thereafter. Additionally, the contract contains penalties for late delivery by eLong Power and late payments by the buyer, as well as protections for eLong Power in the case of unilateral termination by the buyer.

09:27 EDT Carbon Revolution secures $25M financing agreement - Carbon Revolution has reached an agreement with Orion Infrastructure Capital for the early release of a further $25 million in five tranches, each equal to $5 million, subject to satisfying certain reserve release conditions. In connection with the release of each of the five tranches of $5 million from escrow, the Company will issue to OIC a warrant to purchase a number of shares equal to 2.5% of the Company's shares outstanding. The incremental $25 million of capital to be funded from OIC is intended to fund the Company as it works to satisfy the growing demand from Carbon Revolution's OEM customers. The Company is making substantial investments in capacity and throughput and has been producing wheels at record rates.

09:25 EDT Pineapple Energy's SUNAation enters installation agreement - SUNation Energy announced that they will be installing a custom roof-mounted solar system on the National Training Center of the Guide Dog Foundation and America's VetDogs, sister national nonprofit organizations, based in Smithtown, New York. The nonprofits breed, raise, train, and place highly trained assistance dogs with individuals with disabilities, free of charge. The solar installation is slated to reduce the nonprofits' operating expenses, allowing more of their resources to go directly towards the services they provide. Guide Dog Foundation and America's VetDogs both receive the highest ratings for financial stewardship and transparency from the leading charitable watchdog organizations. The nonprofits rely on contributions from generous individuals, corporations, service clubs, and foundations to fund its programs and services. The project's costs were significantly offset by a donation from Contract Pharmacal, a global manufacturer of pharmaceutical products, also based on Long Island. In addition to the support from Contract Pharmacal, the project is benefitting from federal Investment Recovery Act funding. Work is expected to begin in July 2024.

09:24 EDT Sellas Life Sciences granted Rare Pediatric Disease Designation for SLS009 - SELLAS Life Sciences Group announced that the U.S. Food and Drug Administration has granted Rare Pediatric Disease Designation to SLS009, a highly selective CDK9 inhibitor, for the treatment of pediatric acute lymphoblastic leukemia. Childhood ALL is a life-threatening disease with a high unmet medical need. Despite significant advances in the treatment of pediatric ALL, relapse continues to be the most common cause of treatment failure. There are patient subpopulations with high-risk and very high-risk features in need of less toxic therapies that would ultimately extend their long-term event-free survival which remains around 50% for very high-risk groups. In clinical trials, SLS009 has demonstrated a very favorable safety profile with complete absence, to date, of any non-hematologic clinical higher-grade toxicities.

09:21 EDT Wallbridge Mining engages ICP Securities for automated market making services - Wallbridge Mining Company announced an agreement to engage the services of ICP Securities to provide automated market making services, including the use of its proprietary algorithm, ICP Premium, in compliance with the policies and guidelines of the TSX Exchange and other applicable legislation. Under terms of the Agreement, ICP will receive a monthly fee, with there being no performance-based factors. No stock options or other forms of equity-based compensation will be granted in connection with the Agreement. ICP and its clients may choose to acquire an interest in the securities of the Company in the future. ICP is an arm's length party to the Company. ICP's market making activity will be primarily aimed at correcting temporary imbalances in the supply and demand of the Company's shares. ICP will be responsible for the costs it incurs in buying and selling the Company's shares, and no third party will be providing funds or securities for the market making activities.

09:20 EDT Broadcom previews highlights of VMware Explore 2024 - Broadcom previewed highlights of VMware Explore 2024, the industry's essential cloud event. VMware Explore 2024 will kick-off in Las Vegas on August 26-29, 2024 at The Venetian Convention and Expo Center. That event will be followed by VMware Explore 2024 in Barcelona, Spain on November 4-7, 2024 at the Fira Gran Via. VMware Explore Las Vegas will include a general session featuring Broadcom leaders, VMware experts, and customers showcasing advancements in private cloud, generative AI, app delivery, and the edge. The event will also offer hundreds of user-driven panels, certification training, and labs on industry and technology topics. Content will cover advanced cloud solutions for infrastructure modernization, accelerating app development, comprehensive networking and security, and other innovation topics such as private AI. For those that are unable to attend the Las Vegas conference in-person, Broadcom will live stream the general session on August 27, 2024.

09:19 EDT Solitario COO Walter Hunt to retire - Walter Hunt, Solitario's COO, will be retiring from Solitario at the end of June. Walt has been with the Company for over 30 years directing various exploration, development and permitting activities for Solitario. Solitario recently expanded its Golden Crest project management team with the addition of Sandor Ringhoffer. Sandor comes to Solitario with over 36 years in the gold exploration arena, 19 years of which were spent with Agnico Eagle. Most recently, Sandor was project manager for Agnico Eagle's Gilt Edge gold mine re-evaluation project in the Black Hills.

09:17 EDT Solitario receives final USFS approval on plan for Golden Crest Gold project - Solitario Resources announced that its final revised Plan of Operations for its Golden Crest project has been signed by US Forest Service. Additionally, the South Dakota Board of Minerals has accepted Solitario's reclamation bond paving the way for exploration drilling to begin. We are now in the process of mobilizing drilling equipment and organizing support equipment necessary for our drilling operations. Several drill targets are planned to be tested, including Downpour, Whirlwind, Matchstick and Mirage. None of these high-quality gold targets have ever been drilled before.

09:14 EDT Verizon Frontline showcases advanced communications solutions at TechNet Cyber - Verizon Frontline will demonstrate a number of innovative solutions designed to deliver mission-critical communications capabilities to public safety, government and military agencies during AFCEA's annual TechNet Cyber event. Taking place June 25-27 at the Baltimore Convention Center, AFCEA TechNet Cyber brings together leaders from all areas of government to discuss the policy, strategic architecture, operations and command & control - along with the joint capabilities-needed to meet global security challenges and successfully operate in a digital environment. During the TechNet Cyber, Verizon Frontline will showcase its Tactical Humanitarian Operations Response platform, an innovative deployable asset built to provide public sector partners - including the Department of Defense and first responders - with the full range of Verizon Frontline technology. With capabilities ranging from mobile, private 5G ultra wideband, to satellite, to commercial and onboard drone options, to the ability to be operated remotely from a tablet, THOR could be considered the multi-tool of Verizon Frontline assets.

09:12 EDT Shineco enters into securities purchase agreement for gross proceeds of $7M - Shineco, entered into a Securities Purchase Agreement with certain non-U.S. investors. Pursuant to the SPA, the Company will issue up to 1,400,000 shares of its common stock to the Purchasers in a private placement financing transaction at an offering price of $5.00 per share. The gross proceeds of the Offering are expected to be approximately $7,000,000, before the deduction of customary expenses. The Purchasers are a former related party of the Company, who agreed to purchase 1,000,000 shares of common stock, a management member of the Company, who agreed to purchase 200,000 shares of common stock, and an individual investor who agreed to purchase 200,000 shares of common stock. The Offering is expected to close, and the Shares are expected to be issued, on or about July 31, 2024. The Company plans to use the proceeds from this offering for working capital and general corporate purposes, further bolstering the execution of its strategic initiatives.

09:10 EDT Sitka announces acquisition of Victoria Gold's Clear Creek Property - Sitka Gold announces that the Company has executed a definitive asset purchase agreement with Victoria Gold Corp. dated June 24, 2024 in connection with the acquisition of a 100% interest in the Clear Creek property, located adjacent to the Company's RC Gold Project. The Clear Creek Property claims adjoin Sitka Gold's road accessible RC Gold Project located approximately 100 kilometres east of Dawson City, Yukon and cover the southern portion of the Clear Creek Intrusive Complex. The Property encompasses several regions of intrusion-related gold mineralization that have undergone various levels of exploration, including historical reverse circulation and diamond drilling. Pursuant to the Purchase Agreement, the Company issued to Vendor an aggregate of 21,843,401 common shares in the capital of the Company as an initial payment, representing 8% of the issued and outstanding shares of Sitka after giving effect to the issuance of the Shares. In order to complete the Acquisition, the Company is required to make the following additional payments: $2,000,000 on or before August 30, 2025; $3,000,000 on or before June 24, 2026; and $6,000,000 on or before June 24, 2027. During the term of the Purchase Agreement while the Deferred Payments are pending, Sitka will act as operator of the Clear Creek Property and have control over its work programme. The Company may, in its sole discretion, satisfy any Deferred Payment in cash or through the issuance of such number of Shares as is equal to the amount of the applicable Deferred Payment based on the volume weighted average price of the Shares on the TSX Venture Exchange for the 20 consecutive trading days immediately prior to the due date of the applicable Deferred Payment, provided however that in the event that any such Share issuance would result in the Vendor holding greater than 19.9% of the issued and outstanding Shares of the Company, the Company must first obtain: the written consent of the Vendor to receive such Shares; and approval of the shareholders of the Company in accordance with Exchange policies. As additional consideration, upon completion of the Acquisition, the Company will grant to the Vendor a 5.0% net smelter return royalty on the Property. The Company shall have the right at any time following the grant of the NSR Royalty to purchase from the Vendor 60% of the NSR Royalty by way of a one-time cash payment of $10,000,000. In the event that the Company publicly delineates proven and probable mineral reserves of 2,000,000 ounces or more of gold or gold equivalent on the Property, then the Company shall make an additional payment of $10,000,000 in cash to the Vendor within 60 business days of such public delineation. In the event that the Company has not made such public delineation before the fifth anniversary of the Purchase Agreement, then the Vendor shall have the right to cause an evaluation by an independent qualified personto be conducted as to the extent of the mineral resources on the Property, and, in the event such qualified person determines the existence of measured and/or indicated resources of 2,000,000 ounces or more of gold or gold equivalent on the Property, then the Company shall make the $10,000,000 cash payment to the Vendor within 60 business days. In connection with the Purchase Agreement, the parties have entered into an investor rights agreement pursuant to which, among other things: at any time in which the Vendor shall have beneficial ownership of at least 15% of the issued and outstanding Shares of the Company, the Vendor shall have the right to nominate one director to the board of directors of the Company; and the Vendor has been granted certain customary anti-dilution and registration rights.

09:08 EDT NN, Inc. appoints Chris Bohnert as Chief Financial Officer - NN announced the appointment of Chris Bohnert as Chief Financial Officer, effective June 25 Bohnert brings over 30 years of global manufacturing leadership experience as an accomplished CFO with significant experience in successful business transitions and deep accounting expertise. Bohnert will report directly to NN's Chief Executive Officer, Harold Bevis. Bohnert succeeds Mike Felcher, who is departing the company to pursue other opportunities. Felcher will stay on as a consultant to assist with the transition. "Chris's deep experience in manufacturing company turnarounds, IT, investor relations, and banking will make an immediate impact," said Harold Bevis, President and CEO of NN, Inc. "Chris and I have worked together before and now is the right time to make this change. We are going to both pick up the pace and broaden our objectives. Chris is operationally savvy, proactive and has a track record of delivering results. This will be an accelerator for NN's transformation."

09:06 EDT MoneyLion appoints Kaplan as Chief Revenue Officer - MoneyLion (ML) announced the appointment of Jon Kaplan as the company's first Chief Revenue Officer, CRO. Kaplan brings a wealth of experience and a proven track record of driving growth and innovation at iconic technology companies, including Pinterest (PINS).

09:06 EDT Velo3D announces Mears Machine has acquired a Sapphire XC printer - Velo3D announced Mears Machine Corporation, a leader in precision machining solutions, has acquired a Sapphire XC printer to bolster its additive manufacturing capabilities. This strategic investment underscores Mears Machine's commitment to adopting advanced manufacturing technologies and follows the previous purchase of two Velo3D Sapphire XCs announced earlier this year. "As precision machine shops look to adopt advanced manufacturing technologies, like 3D printing, we are pleased to support their mission to modernize and better serve their customers," said Brad Kreger, CEO of Velo3D. "We are thrilled to partner with Mears Machine as they integrate a third Sapphire XC printer into their operations. Our technology is designed to empower manufacturers like Mears Machine to achieve new levels of productivity and innovation through additive manufacturing."

09:04 EDT Houlihan Lokey announces Kraft has joined as Managing Director - Houlihan Lokey announced that Kenny Kraft has joined the firm's Consumer, Food & Retail Group as a Managing Director. Based in Atlanta, Kraft will oversee the firm's coverage efforts across the retail and multi-unit sector, adding expertise in convenience stores, restaurants, and auto-related multi-unit companies.

09:03 EDT America Movil to acquire a controlling interest in ClaroVTR - America Movil (AMX) and Liberty Latin America (LILA) announce that, subject to obtaining the required approval from the National Economic Prosecutor's Office of the Republic of Chile, America Movil will be consolidating ClaroVTR into its ongoing operations. As previously disclosed, AMX has been providing funding to ClaroVTR through convertible notes to support the execution of its business plan and for the refinancing of certain bank debt existing at the formation of the JV and Liberty Latin America had the right to catch-up its respective portion of such funding commitments by the middle of this year for ClaroVTR to continue as a 50:50 joint venture.

09:03 EDT HUB Security 'on track' to release financial reports within next few weeks - HUB Cyber Security released the following statement regarding the recent announcement published on May 23, 2024: "The Company is on track to release its annual financial reports within the next few weeks. Additionally, the Company has recently secured two deals with governmental entities, highlighting its commitment to strategic expansion and enhancing its offerings. Looking ahead, the Company anticipates significant progress in its secure data fabric vertical by the end of the next quarter."

09:02 EDT Real Good Food launches Seasoned Chicken Breast Chunks in 4,000 Walmart stores - The Real Good Food Company (RGF) announced the national launch of its Garlic Parmesan and Lightly Buttered Seasoned Chicken Breast Chunks into the frozen poultry section of approximately 4,000 Walmart (WMT) stores nationwide.

09:01 EDT Actelis Networks expands with 'cyber-hardened IoT airport orders - Actelis Networks announced that it has received new orders to provide its cyber-hardened hybrid-fiber networking solution for international airports based in India, Japan, and Poland. These orders are part of its previously announced multi-year contract with SITA, a global leader in airport operations management systems. This announcement follows a number of recent achievements announced just in the past few weeks, including new orders received from three military bases, a recently announced partnership with Carahsoft to expand Actelis' footprint in US Government Agencies, and a new order and delivery to the City of Bakersfield, California..."We are very proud of the continued expansion of our cutting-edge solutions across international airport networks globally through our partnership with SITA," reflects Tuvia Barlev, Chairman and CEO of Actelis. "As the IoT industry rapidly expands and cyber threats grow, Actelis is in a unique position to help the industry quickly move forward, with both cost-effective, smart IoT implementation, as well as cybersecurity enhancement to legacy networks. Our work with SITA is a great example of Actelis' hybrid-fiber networking offering being introduced into the worldwide market, with a global operator, thus making a difference across an entire industry. With Actelis' solutions, SITA can implement its vision of operational excellence, and enhanced cybersecurity in Airports across the globe, on time and under budget."

09:00 EDT Akebia names Erik Ostrowski as CFO, Chief Business Officer - Akebia Therapeutics announced the appointment of Erik Ostrowski as Senior Vice President, CFO and Chief Business Officer. Ostrowski is an experienced biotech executive with a diverse background spanning industry leadership roles, board service and investment banking. Ostrowski joins Akebia from Avrobio, where he served as President, Interim CEO and CFO, leading the execution of its merger with Tectonic Therapeutic.

08:58 EDT BARDA selects Edesa Biotech drug for U.S. funded platform trial in ARDS - Edesa Biotech announced that its first-in-class drug candidate has been selected by the Biomedical Advanced Research and Development Authority, part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, for evaluation in a U.S. government-funded clinical study. Edesa's drug paridiprubart represents a new class of HDTs that are designed to modulate the body's own immune response when confronted with known or unknown public health threats such as pandemic influenza, COVID-19, other emerging infectious diseases, and chemical, biological, radiological, and nuclear incidents. Importantly, HDTs are agnostic to the causal agent and can be stockpiled preemptively to respond to public health emergencies and biodefense. The BARDA-funded Phase 2 platform trial will be a randomized, double-blinded, placebo-controlled, multi-center U.S. clinical trial to investigate three novel threat-agnostic host-directed therapeutics, including paridiprubart, in hospitalized adult patients with ARDS. The BARDA study of paridiprubart is expected to build on the success of a Phase 2 clinical study that the company completed during the COVID-19 pandemic which demonstrated that paridiprubart reduced mortality by 84% among critically ill ARDS patients. A parallel study using an in vitro model also demonstrated that paridiprubart inhibits a key mediator of inflammatory responses from influenza and other pathogens. A separate Edesa-sponsored Phase 3 study of paridiprubart in patients with ARDS due to SARS-CoV-2 infection is currently ongoing in Canada and the U.S. The BARDA-funded study will be managed under a BARDA contract with PPD Development, LP, a clinical research business of Thermo Fisher Scientific, Inc. For the paridiprubart cohort of the study, patients will be randomized one-to-one to either paridiprubart plus Standard of Care or to a placebo plus SOC control arm. Edesa will provide drug products to the study as well as technical support

08:55 EDT Principal Solar partner eTruck to deploy hybrid-converted semis by year-end - Principal Solar announced that its Royalty Agreement Partner, eTruck Transportation, expects to begin producing powertrains that turn Class 8 diesel trucks into hybrid battery-electric vehicles by the end of 2024. The powertrain systems are already available for order, and eTruck plans to start commercial production by the end of the year, eTruck company President Russell Knudsen told Transport Topics.

08:53 EDT Biofrontera Inc. announces launch of RhodoLED XL lamp - Biofrontera announced the launch of its FDA-approved RhodoLED XL, a red light emitting LED lamp. This device represents a significant advancement in the treatment of PDT with state-of-the-art engineering, robust but sleek construction and an intuitive user interface. It is designed to be simple to maneuver and able to accommodate various patient treatment positions in order to optimize ease of use. Biofrontera's PDT drug, Ameluz, is approved by the FDA in combination with either member of the RhodoLED lamp family. The introduction of the RhodoLED XL provides the option to illuminate a larger area in a single on-label Ameluz PDT treatment.

08:51 EDT Matinas BioPharma reports treatment of patient with mucor infection with MAT2203 - Matinas BioPharma Holdings announces the recent treatment of a 22-year-old male with polymicrobial necrotizing fasciitis that involved drug-resistant Lichtheimia, an angio-invasive species of the fungus Mucorales. This patient was treated at New York Presbyterian/Weill Cornell Medical Center and was discharged after just six weeks of treatment with MAT2203, Matinas' oral formulation of the potent antifungal amphotericin B. The patient was treated under Matinas' Compassionate/ Expanded Use Access Program by Sharan Yadav, MD, Infectious Disease Fellow. A total of 24 patients are currently receiving or have completed treatment with MAT2203 under the Compassionate/Expanded Use Access Program, and four additional cases are awaiting submission and/or FDA approval. In each instance, the patient was not responding to azole therapy, was unable to receive azole therapy due to drug/drug interactions or was unable to tolerate IV-amphotericin B for an appropriate treatment duration due to toxicity. In all patients who experienced serious renal toxicity while receiving IV-amphotericin B who were subsequently treated with MAT2203, renal toxicity was reversed, and renal function returned to baseline.

08:50 EDT Imunon announces database kock for Phase 2 studyof IMNN-001 in OC - IMUNON announces database lock for its Phase 2 OVATION 2 Study evaluating the safety and efficacy of IMNN-001 in patients with advanced ovarian cancer. Median Overall Survival OS and Progression Free Survival PFS have been reached and all patients in the open-label study have achieved treatment observation duration of 16 months, as required per protocol to evaluate efficacy. The independent statisticians have received the raw trial data and will follow the statistical analysis plan as they analyze the data from the trial. IMUNON expects to report topline results including hazard ratios before the end of July 2024. OVATION 2 is evaluating the dosing, safety, efficacy and biological activity of intraperitoneal administration of IMNN-001 in combination with neoadjuvant chemotherapy NACT in patients newly diagnosed with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer. Treatment in the neoadjuvant period is designed to shrink the tumors as much as possible for optimal surgical removal after three cycles of chemotherapy. Following NACT, patients undergo interval debulking surgery, followed by three additional cycles of adjuvant chemotherapy to treat any residual tumor. Patients were randomized 1:1 and evaluated for safety and efficacy to compare NACT plus IMNN-001 versus standard-of-care NACT. Patients randomized to the IMNN-001 treatment arm received up to 17 doses of 100 mg/m2, in addition to NACT. Full enrollment of 110 patients was reached in September 2022.

08:49 EDT Nano Nuclear Energy acquires novel ALIP intellectual property - NANO Nuclear Energy announced its acquisition of novel annular linear induction pump intellectual property used in small nuclear reactor cooling and heat transfer from noted physicist, research engineer and project manager Carlos O. Maidana, PhD. of Maidana Research. Dr. Maidana has agreed to collaborate with NANO Nuclear as a consultant on further development of the ALIP technology with a view towards achieving SBIR Phase III Award status. These efforts will build on previous Department of Energy grants for the technology, aggregating over $1.37 million in prior phases. NANO Nuclear will provide funding and other resources necessary for the Phase III project, and Dr. Maidana will be the Principal Investigator on this project. The ALIP technology, which is based on electromagnetic pumps, is a key-enabling technology to NANO Nuclear's ODIN', a clean energy, portable micro nuclear reactor in development. Following the previously announced completion of Idaho National Laboratory's review of the 'ODIN' microreactor design in February 2024, NANO Nuclear engineers have diligently worked to identify relevant technologies to further optimize and simplify ODIN's design. The acquired ALIP technology, to be refined during the SBIR Phase III program, is an example of this strategy in action.

08:47 EDT Lead Real Estate announces plans for construction of 'Premium Series' hotel - Lead Real Estate announced plans to build the ENT TERRACE brand's first "Premium Series" hotel, ENT TERRACE GINZA PREMIUM, in Tokyo, Japan. The upcoming facility will have seven floors and six guest rooms, and accommodate from one night to long-term stays beginning in December 2024. Located about two minutes by walk from Higashi-Ginza Station on the Toei Asakusa Line. The current weak yen and increasing foreign interest in Japan, said LRE, are expected to continue their positive impact on the Company's expanding long-stay business.

08:46 EDT Anixa Biosciences treats sixth patient in ovarian cancer CAR-T clinical trial - Anixa Biosciences announced that it has treated the sixth patient in the ongoing Phase 1 clinical trial of its novel chimeric antigen receptor T-cell therapy for ovarian cancer. This patient is expected to be the last patient in the second dosage cohort. If there continue to be no adverse effects experienced by the second cohort participants, enrollment of the third dosage cohort may commence within the next month. The study is being conducted through a research partnership with Moffitt Cancer Center.

08:45 EDT AST SpaceMobile welcomes Sambar to board of directors - AST SpaceMobile announced the appointment of Chris Sambar to its Board of Directors, effective June 20, succeeding Alex Coleman, Chairman at New Providence Acquisition Corp. Sambar brings a distinguished career in leadership and technology to AST SpaceMobile, further strengthening the company's expertise as it prepares for its next phase of growth.

08:45 EDT OSI Systems receives $11M order for mobile cargo, vehicle inspection systems - OSI Systems announced that its Security division received an order valued at approximately $11M to provide multiple units of the Eagle M60 mobile high-energy cargo and vehicle inspection system, including follow-on maintenance and support. The inspection systems are expected to be used for international border and security requirements. OSI Systems' Chairman and CEO, Deepak Chopra, stated, "We are thrilled to receive this award as it highlights the trust and confidence in our advanced inspection technologies. The Eagle M60 platform offers tremendous flexibility, allowing users to swiftly relocate checkpoints to enhance security measures efficiently."

08:43 EDT Creative Medical Technology announces development of IPSCelz program - Creative Medical Technology Holdings has generated human induced pluripotent stem cells-derived Islet Cells that produce human insulin. The iPSC clinical line that generated these insulin producing Islet Cells is part of the Company's iPSCelz program, which is validated by Greenstone Biosciences. The iPSC clinical line, which is currently utilized in a number of our FDA cleared clinical programs in the U.S., has also been utilized to derive validated mesenchymal cells and T-regulatory cells.

08:40 EDT Highest Performances says Puyi Fund asset allocation portfolio exceeded RMB24B - Highest Performances Holdings announced that the portfolio balance of the asset allocation services of its majority-owned subsidiary Fanhua Puyi Fund Distribution has reached RMB24.7 billion as of June 21, 2024, representing a year-over-year growth of 188% from June in 2023. This achievement stems from its relentless efforts in product strategy adjustments and digital transformation. The Company introduced a comprehensive family wealth management account system, shifting its focus to fixed-income fund products and fund portfolio products to offer clients a more stable and secure wealth-building experience. It recommends investors allocate 50% to 80% of their funds to "Steady Growth" accounts, aiming for steady asset appreciation while minimizing risks. This approach aligns with the current market trend in China, where investors are more inclined to a lower risk appetite.

08:38 EDT Saputo completes sale of two fresh milk processing facilities in Australia - Saputo has completed the previously announced sale of two fresh milk processing facilities located in Laverton North, Victoria, and Erskine Park, New South Wales, to Coles Group Limited, an Australian-based supermarket, retail, and consumer services chain, in a transaction valued at approximately CDN$95 million. The completion of this transaction is part of the Company's overall network optimization strategy, one of the pillars of its Global Strategic Plan. As part of the sale, Saputo is maintaining its valued farmer relationships in Australia and will continue to have fresh milk products processed at the two manufacturing facilities. The employment of approximately 48 people across the two sites was transferred to Coles Group Limited.

08:36 EDT Nuburu announces 1-for-40 reverse stock split - NUBURU announced that it will continue its previously announced plan to implement a 1-for-40 reverse stock split of its common stock, with an anticipated implementation date of July 1, 2024, rather than the previously announced June 24, 2024 anticipated implementation date. Due to the NYSE halting trading in the common stock upon the initial announcement of the Reverse Split, the Company was unable to implement the Reverse Split as announced. The Company is in the process of appealing the NYSE's determination to initiate proceedings to delist its common stock and is being traded on the over-the-counter market under the symbol "BURU" in the meantime. "Our decision to execute this reverse stock split is part of our strategic plan to improve the marketability and liquidity of our stock, as we aim to attract a broader range of institutional investors in support of our long-term growth strategy, and return to trading on NYSE American," said Brian Knaley, CEO of NUBURU, Inc.

08:35 EDT Silence Therapeutics achieves $2M research milestone payment from Hansoh Pharma - Silence Therapeutics announced that it will receive a $2M cash payment from Hansoh Pharmaceutical Group Company Limited following the achievement of a second undisclosed milestone related to the first target under the collaboration. "This represents an important milestone in our efforts to advance this program into the clinic with Hansoh," said Craig Tooman, President and CEO of Silence. "This is an exciting time for Silence and our mRNAi GOLD platform as we continue to advance and expand our pipeline targeting a wide range of genetic diseases."

08:33 EDT ODP and Telos announce new TSA PreCheck enrollment locations - Office Depot, an operating company of The ODP Corporation (ODP)and a leading omnichannel retailer dedicated to helping its small business, home office and education customers live more productive and organized lives, and Telos Corporation (TLS), an authorized TSA PreCheck enrollment provider, today announced additional TSA PreCheck enrollment locations with the opening of five new locations at Office Depot retail stores in Georgia, Tennessee and Texas beginning on June 2 . This follows the previous addition of 20 new locations since May 2024 in states including Arizona, California, Colorado, Texas and Washington.="Aligned with our focus on providing a variety of solutions to our clients, we are excited to partner with Telos Corporation to provide TSA PreCheck enrollment services," said Kevin Moffitt, executive vice president of The ODP Corporation and president of Office Depot. "Providing the convenience and ease to enroll in the TSA PreCheck program through our nationwide retail store locations is ideal for anyone looking to simplify their air travel experience. We are excited to expand this service, along with other travel essentials, to more stores in the near future."

08:33 EDT Mira Pharmaceuticals announces new results for Ketamir-2 - Mira Pharmaceuticals announced new compelling preclinical results for its investigational compound, Ketamir-2, a novel oral ketamine analog. The new data highlights Ketamir's potential to provide therapeutic benefits without inducing schizophrenia-like behavior or hyper-locomotor activity. MIRA conducted the latest rigorous preclinical studies in collaboration with Biotrial to evaluate the effects of Ketamir-2 on spontaneous locomotor activity in mice. The studies are particularly significant for the treatment of mental health disorders and pain management, presenting a major advancement in the development of safer and more effective therapeutic options. Key findings from the study: Reduced Psychotic-like Symptoms: Unlike traditional ketamine, which resulted in marked and significant hyperlocomotion, Ketamir-2 did not produce incidences of inducing hyperlocomotion, schizophrenia-like behaviors in animal models, indicating a potentially safer profile for human patients, especially those with a predisposition to psychotic disorders. No Hyper-locomotor Activity: The study showed that while traditional ketamine induced hyperlocomotion, Ketamir-2, at same and higher doses compared with traditional ketamine, did not result in the hyper-locomotor activity, reducing the potential for misuse and enhancing patient safety. MIRA is on track to submit an IND application for Ketamir-2 to the FDA by the end of this year.

08:29 EDT A-Mark acquires additional 8% interest in Silver Gold Bull for $9.6M - A-Mark Precious Metals has acquired an additional 8% of the outstanding equity interest in Calgary-based Silver Gold Bull for approximately $9.6 million. The investment brings A-Mark's ownership in SGB to 55.4% and continues to expand A-Mark's direct-to-consumer footprint in the international market. A-Mark acquired its initial stake in SGB in 2014, increasing its investment to 47.4% in 2022. Founded in 2009, SGB is a leading e-commerce precious metals retailer in Canada focused on providing online innovation, high-quality products, competitive pricing, and excellent customer service. Transaction Summary: A-Mark paid approximately $9.6 million for an additional 8% of the outstanding equity interest in SGB. A-Mark's previous option to increase its ownership interest in SGB has been reduced from 75% to 70%. The option, previously set to expire in September 2024, has been extended to September 2025. Employment agreements have been entered into with key SGB management, including Nikolas Morianos, Mihali Belandis and President and Co-Founder Bob Belandis. SGB financial and operational highlights for the fiscal year ended April 30, 2024, include: Net sales of $467.9 million, gross profit of $20.8 million and pre-tax income of $4.2 million. Sold more than 7.85 million ounces of silver and 151,000 ounces of gold. Added approximately 53,000 new customers, for a total of 520,000 customers as of April 30, 2024. Processed approximately 105,000 orders.

08:26 EDT Fangdd Network to acquire patents on cloud computer technology for $35M - Fangdd Network Group had entered into an agreement to purchase certain patents relating to cloud computer technology in China. The transaction is part of the Company's strategy to expand into technology-enabled real estate management as a supplement to its existing business. The purchase price for the patents is $35,000,000. Additionally, the seller is entitled to receive an earnout payment for each fiscal year ending on December 31, 2024, December 31, 2025 and December 31, 2026 at an amount equal to $15,000,000 multiplied by the ratio of the revenue generated by the patents during such year to RMB108,450,000. The total amount of the earnout payments for all three years combined shall not exceed $15,000,000. The Company will have three months to raise funds for the purchase and complete the transaction. If the transaction does not close by September 21, 2024, either party may terminate the agreement by providing written notice, without incurring liability to the other party. The purchase agreement contains representations, warranties and other provisions customary for transactions of this nature.

08:23 EDT Recursion Pharmaceuticals gives guidance on seven clinical readouts - Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, will give updated pipeline guidance to investors, analysts, and other stakeholders during Download Day, Recursion's investor and R&D day, on Monday, June 24, 2024. The event will feature a number of prominent speakers, including Jensen Huang, founder and CEO of NVIDIA, Deepak Nijhawan, M.D., Ph.D., UT Southwestern Distinguished Chair in Biomedical Science, and John Marioni, Ph.D., Senior VP and Head of Computational Sciences at Genentech. Updated pipeline guidance: Seven Clinical Trial Readouts expected within approximately 18 months: REC-994 Cerebral Cavernous Malformation-topline Phase 2 data readout in September 2024; REC-2282 Neurofibromatosis Type 2-preliminary Phase 2 data readout in the fourth quarter of 2024; REC-4881 Familial Adenomatous Polyposis-preliminary Phase 2 data readout in the first half of 2025; REC-4881 Advanced AXIN1/APC-Mutant Cancers-preliminary Phase 2 data readout in the first half of 2025; REC-3964 Clostridioides difficile Infection-Phase 2 study initiation in the fourth quarter of 2024 and preliminary data readout by the end of 2025; RBM39 Advanced HR-Proficient Cancers-IND submission in the third quarter of 2024, Phase 1/2 initiation in the fourth quarter of 2024 and Phase 1 dose-escalation data readout by the end of 2025; Target Epsilon-IND submission in early 2025 and Phase 1 healthy volunteer study data readout by the end of 2025. Dozens of internal and partner programs in early stages with the first LLM and causal model driven programs entering the Recursion pipeline. Partnership updates: Bayer will be the first beta-user of our LOWE LLM-orchestrated workflow software, which will be integrated across the collaboration and offer a more exploratory, and intuitive research environment for scientists on both sides. Additional updates pertaining to the Bayer partnership include: We initiated our first joint oncology project which is now expected to advance rapidly towards Lead Series nomination; and We are on track to complete 25 unique multi-modal data packages that we expect to deliver in the third quarter of 2024. Platform updates ADME industrialization: potential to achieve an estimated 90 times the amount of lab throughput over a manual approach. Built our first genome-scale transcriptomics knockout map. Multimodal mapping has enabled us in certain experiments to achieve 90% success on our ability to predict compounds that failed later disease-relevant assays in internal tests and 60% ability to predict compounds that passed later disease-relevant assays in internal tests. Helix partnership brings hundreds of thousands of unique de-identified patient records across diverse therapeutic areas.

08:20 EDT OneMedNet enters standby equity purchase agreement with Yorkville - As previously disclosed on Form 8-K filed with the SEC on June 21, 2024, the Company entered into a standby equity purchase agreement with YA II PN, LTD, a Cayman Islands exempt limited partnership managed by Yorkville Advisors Global,, on June 17, 2024. Under the terms of the SEPA, Yorkville committed to purchase up to $25.0 million of the Company's common stock over the next twenty-four-month period, subject to certain conditions and limitations. The purchase price will be at a 3.0% discount. On June 18, 2024, Yorkville advanced $1.5 million to the Company under a convertible promissory note due June 18, 2025. Generally, the Company anticipates that the note will be repaid through SEPA advances initiated by Yorkville at the note conversion price, which will be then applied to the outstanding balance. The Company's right to draw on the SEPA will begin after repayment of the Promissory Note. The Company intends to use the proceeds from the promissory note and the potential offering of the common shares pursuant to the SEPA for working capital and other general corporate purposes. The SEPA supersedes and replaces the Company's definitive securities purchase agreement with Helena Global Investment Opportunities 1 Ltd., which had provided for up to $4.54 million in funding through a private placement for the issuance of senior secured convertible notes, which was terminated on June 14, 2024.

08:18 EDT OneMedNet provides update on auditor change - OneMedNet Corporation provided a number of corporate updates. As previously disclosed via a Form 8-K filed by the Company with the Securities and Exchange Commission on May 10, 2024, on May 6, 2024, the Company dismissed BF Borgers CPA PC as its independent registered public accounting firm. On May 3, 2024, the SEC announced that it had settled charges against Borgers that it failed to conduct audits of a number of public companies in accordance with the standards of the Public Company Accounting Oversight Board. As part of the settlement, BF Borgers agreed to a permanent ban on appearing or practicing before the SEC. On June 3, 2024, the Company appointed WithumSmith+Brown, PC as its new independent registered public accounting firm to audit and review the Company's financial statements.

08:16 EDT CervoMed announces addition to Russell 2000, Russell 3000 Indexes - CervoMed announced its expected addition to the Russell 2000 and Russell 3000 Indexes at the conclusion of the 2024 Russell U.S. Indexes annual reconstitution, effective when the U.S. equity markets open on Monday, July 1, 2024, according to the final preliminary list of 2024 additions posted on the FTSE Russell website on June 21st 2024.

08:16 EDT Stratasys, AM Craft partner to drive growth in 3D manufacturing for aviation - Stratasys and aviation manufacturing pioneer AM Craft announced that they are partnering to align the two companies' efforts to grow the demand for flight-certified 3D printed parts in the aviation industry. The companies signed a definitive commercial collaboration agreement, along with Stratasys' strategic investment in AM Craft.

08:15 EDT Yatra announces independent committee to evaluate potential restructuring - Yatra Online announced that its board of directors is looking to explore certain strategic options regarding simplifying the Company's multi-jurisdictional corporate structure and in that direction has established an independent committee of the board. The committee is expected to engage with industry experts, legal counsel, regulatory bodies, and other stakeholders to gather insights, perspectives, and requirements for approval on any proposed corporate structural changes. After such review, the committee will develop a set of strategic recommendations for the board that outline potential pathways, the anticipated benefits, and any associated risks or challenges. The committee will aim for a plan that can reduce administrative overhead, rationalize costs, and facilitate organic and inorganic growth for the Company. There is no assurance that the Company will necessarily take any near-term course of action, or will pursue any recommended plan.

08:14 EDT Kiniksa, NHL Hall-of-Famer Henrik Lundqvist partner for pericarditis awareness - Kiniksa Pharmaceuticals announced a partnership with National Hockey League Hall-of-Famer, Henrik Lundqvist, to raise awareness in support of patients suffering from recurrent pericarditis. Lundqvist has faced the challenges of living with this painful and debilitating chronic autoinflammatory cardiovascular disease. The campaign will kick off in September of this year.

08:13 EDT Crowdstrike will be added to the S&P 500 Index - CrowdStrike will be added to the S&P 500 Index, making CrowdStrike the fastest cybersecurity company to attain this achievement. CrowdStrike's inclusion in the S&P 500 reflects its track record of industry leadership and innovation, transforming cybersecurity with AI through a single platform that stops breaches. CrowdStrike brought SaaS cybersecurity to the cloud, natively built the Falcon platform with AI from the start and has consistently delivered hyper growth results since its blockbuster 2019 IPO.

08:12 EDT Walgreens optimized operations with Zebra's Workcloud Software - Zebra Technologies (ZBRA) announced that the Walgreens (WBA) Boots Alliance has optimized its operations with Zebra Workcloud Actionable Intelligence software to save millions of dollars by enhancing operational compliance and the company's ability to identify and combat shrink. Walgreens selected Zebra's Modern Store framework to improve asset protection, better equip employees with technology, and optimize operational visibility in their network of 8,000 locations across 50 states. As an essential retailer carrying critical healthcare products and prescription medications, Walgreens needed an intuitive analytics solution to uncover issues and resolve areas of loss in real time.

08:10 EDT One Energy select Cuffe to join One Power Board at business combination closing - One Energy Enterprises, an industrial power company pursuing a business combination transaction with TortoiseEcofin Acquisition Corp. III, announced its selection of Selena Cuffe to join the board of directors of the surviving public company after the proposed business combination, which is expected to be renamed One Power Company. Prior to consummating the Business Combination, TRTL will seek shareholder approval of the transaction, including the appointment of Cuffe and the other director nominees to the One Power Board.

08:09 EDT Soluna Holdings unleashes first batch of NVIDIA GPUs - Soluna (SLNH) announced it has successfully raised a credit facility of $12.5M at its new subsidiary Soluna Cloud, marking the completion of the first tranche in a larger fundraising effort led by BitOoda Technologies and Imperial Capital. This financing will support the launch of Soluna Cloud, and secure NVIDIA H100 (NVDA) GPUs leveraging a 3-year managed-services agreement at a Tier 3 hydro-powered data center in collaboration with the Company's Strategic OEM Partner. "This is a pivotal point for Soluna Cloud as we are now able to open our waitlist for this highly anticipated business at Soluna. AI is set to transform the enterprise, and Soluna is making a vital contribution to making it a climate-friendly reality," said John Belizaire, CEO of Soluna.

08:07 EDT Byrna Technologies names Lauri Kearnes as Chief Financial Officer - Byrna Technologies (BYRN) has appointed Lauri Kearnes as Chief Financial Officer CFO , effective July 15...Kearnes is already working with the Company to ensure a smooth transition. Kearnes brings over 20 years of experience in financial and operating leadership, most recently serving as CFO for Harte Hanks (HHS), a Massachusetts-based global customer experience strategy company. At Harte Hanks, she oversaw all finance, accounting, and human resources for a business with over $200 million in annual revenues.

08:06 EDT Enlivex Therapeutics doses first patient in Phase I/II trial of Allocetra - Enlivex Therapeutics announced that the first patient has been dosed in an investigator-initiated, randomized, placebo-controlled Phase I/II trial evaluating the efficacy and safety of Allocetra following injection into patients with basal thumb joint osteoarthritis, for which conventional therapies have failed. This investigator-initiated Phase I/II trial plans to recruit up to 46 patients and is composed of two stages. The first stage is a safety run-in, open-label dose escalation phase to characterize the safety and tolerability of an Allocetra injection in patients with osteoarthritis of the first basal thumb joint of the target thumb to identify the dose for the randomized stage. The second stage is a double-blind, randomized, placebo-controlled stage, which the Company expects to initiate following the completion of the safety run-in stage and selection of the safe and tolerable dose. Up to 40 patients will be randomized in a 1:1 ratio for treatment with either Allocetra at the selected dose or placebo. The primary safety endpoint will measure the frequency and severity of adverse events and serious adverse events, and the efficacy endpoints will include assessments of change from baseline in pain and function for up to 12 months following treatment.

08:05 EDT Seven Hills Realty Trust announces it will be added to Russell 3000 Index - Seven Hills Realty Trust announced that it will be added to the broad-market Russell 3000 Index at the conclusion of the 2024 Russell U.S. Indexes annual reconstitution, effective after market close of the U.S. equity markets on Friday, June 28, 2024, according to a preliminary list of additions posted by FTSE Russell on June 21, 2024.

08:04 EDT Evolus announces submission of PMA to U.S. FDA for two Evolysse products - Evolus announced that it has submitted the final module of its premarket approval, PMA, application to the U.S. Food and Drug Administration, FDA, for the Evolysse Lift and Evolysse Smooth dermal filler products for the nasolabial fold, NLF. The PMA application includes results from the U.S. pivotal study, which evaluated the safety and effectiveness of the products in a multicenter, blinded, split face, controlled, non-inferiority designed trial. Patients were followed for 12 months from initial treatment. A total of 140 patients were enrolled and divided evenly across two investigational arms. Patients were randomized to receive Evolysse Lift or Evolysse Smooth in one NLF and Restylane-L in the contralateral NLF. This split face design allowed each individual patient to experience one of the Evolysse fillers and the control at the same time.

08:03 EDT PetMed Express appoints Leah Solivan to board of directors - PetMed Express announced the appointment of Leah Solivan to the Company's Board of Directors, effective June 24, 2024. Solivan brings over 20 years of experience building and scaling technology businesses to the Company's Board. As a General Partner at Fuel Capital, she focuses on early-stage investments across a variety of sectors, including consumer technology, hardware, education, marketplaces, and retail.

08:01 EDT Taoping receives Nasdaq notice of non-compliance - Taoping announced that on June 21, 2024, it received a written notification letter from The Nasdaq Stock Market notifying the company that it is currently not in compliance with the minimum bid price requirement set forth under Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share.

08:00 EDT CSG increases purchase price for The Kinetic Group to $2B - Vista Outdoor announced that, on June 23, 2024, it entered into an amendment to the merger agreement with Czechoslovak Group, CSG. The amended agreement further increases the base purchase price payable by CSG for the acquisition of The Kinetic Group business by $40 million from $1.96 billion to $2 billion and increases the cash consideration payable to Vista Outdoor stockholders by $2.00 per share of Vista Outdoor common stock from $16.00 to $18.00 in cash, a 12.5% increase. Based on the amended merger agreement with CSG, Vista Outdoor stockholders will receive at the closing of the CSG Transaction, per share of Vista Outdoor common stock, one share of Revelyst common stock and $18.00 in cash. Vista Outdoor is confident that the CSG Transaction will maximize value for our stockholders by: Providing for a $2 billion purchase price, representing a $90 million increase from the original $1.91 billion purchase price, Allowing stockholders to benefit directly from additional excess cash generated by the Company prior to closing, Delivering $18.00 in cash consideration per share at closing, representing a $5.10 increase from the original cash consideration of $12.90 per share, and Enabling stockholders to capture the long-term intrinsic value that is embedded in Revelyst's business plan as a standalone public company

07:58 EDT DocGo secures five new contracts - DocGo announced it has secured five new contracts that include remote patient monitoring, virtual care management, chronic care management, cardiac implantable electronic device, and a care gap closure program for a national health plan. These noteworthy examples of new DocGo contracts expand the Company's reach and ability to deliver quality virtual, in-person, and mobile healthcare services.

07:39 EDT Indonesia Energy commences 3D seismic operations at Kruh Block - Indonesia Energy Corporation provided an operational update and announced that new 3D seismic exploratory operations at its 63,000 acre Kruh Block have commenced. Importantly, IEC anticipates that the results of this seismic work will allow IEC to drill new production wells at Kruh Block the by the end of 2024. Additionally, IEC announced that key environmental permits have been granted at IEC's 650,000 acre Citarum Block where reserves could potentially exceed a billion barrels of oil equivalent. IEC's receipt of these permits represents an important milestone for IEC as the permits will allow for meaningful exploratory work by IEC at Citarum for the first time. As the operator of the Kruh block, IEC's 3-D seismic program will cover the Kruh, North Kruh and West Kruh Fields. This 29 square km high-quality seismic program is strategically focused on existing proved reservoirs of the Talangakar and Lemat formations, as well as the very large and promising shallow oil/gas zones in the K-28 well discovered by IEC's work in 2022. The new, high quality three-dimensional seismic data will enable the identification of additional locations of proved undeveloped reserves and resources. This in turn will pave the way to prioritize the sequence of upcoming drilling locations as IEC recommences drilling operations at Kruh Block. Preparations for the new drilling operation are underway, with plans to drill the first well in the fourth quarter of 2024 after the evaluation of the new three-dimensional seismic data is completed. IEC announced in September 2023 that its joint operation contract with Pertamina, the Indonesian state-owned oil and gas company, covering the Kruh Block was extended by 5 years from May 2030 to September 2035. Kruh Block covers approximately 63,000 acres and is located onshore on the Island of South Sumatra in Indonesia. The amended joint operation contract has the following key terms: The amended contract increases IEC's after-tax profit split from the current 15% to 35%, for an increase of more than 100%. In addition, given the 5-year extended term of the contract, the amended contract is expected to increase IEC's proved reserves at Kruh Block by over 40%. Furthermore, given the increased profit split, IEC's anticipated net cash flow calculations based on its Kruh Block development plan are expected to increase by over 200% versus IEC's anticipations under the prior contract. At Citarum Block, IEC's receipt of government environmental permits to commence seismic operations which are planned for late this year or early next year, with plans to also commence drilling next year. As required by government regulations, IEC relinquished approximately 35% of its original Citarum acreage but has retained approximately 97% of the original prospective resources and now has approximately 650,000 acres on which drilling could take place. As previously reported, IEC's estimates are that the Citarum Block has prospective oil-equivalent resources of over one billion barrels of oil.

07:38 EDT Kura Oncology data supports potential for menin inhibitor in diabetes treatment - Kura Oncology reported preclinical data supporting the potential therapeutic utility of menin inhibitors in the treatment of diabetes. The new findings were presented this weekend at the American Diabetes Association's 84th Scientific Sessions in Orlando. Copies of the presentation are available in the Posters and Presentations section on Kura's website. "Despite the introduction of multiple options for the treatment of type 2 diabetes, a significant unmet need exists as a large proportion of patients do not achieve glycemic control," said Francis Burrows, Ph.D., Senior Vice President, Translational Research. "We are encouraged by these preclinical data for ziftomenib in diabetes, which demonstrate the potential for menin inhibitors to enhance pancreatic function and warrant further evaluation in diabetes."

07:35 EDT Great Elm Capital raises $12M of equity at net asset value - Great Elm Capital Corp. announced it issued approximately 1.0 million shares of the Company's common stock at a current net asset value of $12.03 per share, for an aggregate gross purchase price of $12 million, to Prosper Peak Holdings. Great Elm Group, the parent of the Company's investment manager, made a $3 million investment in PPH, further aligning it with shareholders.

07:35 EDT Viking Therapeutics presents data on amylin and calcitonin receptors - Viking Therapeutics announced the presentation of preclinical data from a series of internally developed dual agonists of the amylin and calcitonin receptors at the 84th Scientific Sessions of the American Diabetes Association. The presentation highlights the effects of treatment on body weight, food intake and metabolic profile in healthy rats and diet-induced obese mice as compared to control cohorts treated with vehicle or the dual amylin and calcitonin receptor agonist cagrilintide. The studies were summarized in a poster presentation at the annual scientific conference of the American Diabetes Association, being held June 21-24, 2024, in Orlando, Florida. The study results demonstrate that Viking's series of dual amylin and calcitonin receptor agonists reduced food intake in lean rats in the period from 0-72 hours following a single subcutaneous dosing. At 72 hours following a single subcutaneous dose, Viking's novel compounds resulted in up to 8% body weight reductions compared to vehicle-treated animals. In a DIO mouse model, treatment with Viking's series of co-agonists for 24 days resulted in body weight reductions that were comparable to those achieved in cagrilintide-treated animals. Additionally, improvements in key metabolic markers, including blood glucose levels, were observed in DIO mice treated with the company's compounds for the 24-day time period.

07:31 EDT Agnico Eagle acquires 33,821,842 shares of Maple Gold Mines - Agnico Eagle Mines announced that it acquired 33,821,842 common shares of Maple Gold Mines on June 21, 2024 at a price of 8.5c per Common Share for total consideration of approximately $2,874,856.57 from several sellers that acquired the Common Shares in connection with an offering of flow-through Common Shares issued by Maple. Prior to the Share Purchase, Agnico Eagle owned 40,852,415 Common Shares, representing approximately 11.97% of the issued and outstanding Common Shares on a non-diluted basis. Following the Share Purchase, Agnico Eagle owns 74,674,257 Common Shares, representing approximately 19.9% of the issued and outstanding Common Shares on a non-diluted basis.

07:31 EDT Altus Power acquires 8.5 MW project in New Jersey - Altus Power announced the acquisition of an 8.5 MW solar array in New Jersey. The ground-mounted project generates clean, electric power that will be sold to PJM, the local independent system operator, as well as Solar Renewable Energy Credits, and increases the size of the company's New Jersey portfolio to 185.5 MW in aggregate. "New Jersey is a national leader in renewable energy and we're pleased to expand our footprint in the Garden State," said Gregg Felton, CEO, Altus Power. "This acquisition includes 63 acres of land which enhances our flexibility to redevelop this site in the future and maximize long-term value."

07:24 EDT Omega Therapeutics announces election of Richard Kender to its board - Omega Therapeutics announced the election of Richard N. Kender to its Board of Directors following its annual meeting of stockholders. Mr. Kender's industry knowledge and proven expertise in corporate finance and business development spanning both large pharmaceutical and emerging biotech companies will be instrumental in supporting the Company's business objectives.

07:19 EDT Aclara Resources says Penco Module EIA application admitted for evaluation - Aclara Resources announced that, after a five-business day review period, it has received confirmation of the admissibility of its Environmental Impact Assessment application by the Environmental Service Assessment in Concepcion, Chile. This confirmation marks the first step in the application process. In addition, on June 22, 2024, an extract of the EIA was published by SEA in the Official Gazette. This publication initiates the citizenship participation process, which lasts 60 business days. In parallel, the initial technical review process for the first round of observations is underway and is expected to last approximately 30 business days. Subject to SEA's confirmation that there are no further requirements of material information, the technical assessment will advance to the next phase of the process. The Company anticipates that the EIA will undergo an evaluation period of approximately 18 months and is committed to working with the SEA throughout the assessment and review process.

07:14 EDT TFF Pharmaceuticals submits briefing book to the FDA for TFF TAC development - TFF Pharmaceuticals announced a regulatory update on the Company's TFF TAC clinical program following its recent interaction with the U.S. Food and Drug Administration , FDA.In April 2024, the Company submitted a briefing book to the FDA to help guide the next steps in the clinical development pathway for TFF TAC. Following its review of the briefing book, the FDA concurred that mitigation or prevention of tacrolimus associated toxicities without placing the lung allograft at risk will be an important therapeutic benefit and provided constructive feedback and valuable guidance on the roadmap for advancement of TFF TAC. Based on this feedback, the Company does not expect a significant change to either its timelines or the estimated costs associated with the clinical advancement of TFF TAC. "The initial feedback from the FDA on the TFF TAC clinical program has provided us with additional clarity on how we can continue advancing this innovative product towards registrational testing," said Dr. Zamaneh Mikhak, Chief Medical Officer of TFF Pharmaceuticals. "Over the next several weeks, we expect to receive additional guidance from the FDA, which should allow us to provide a more detailed regulatory update on the program in the third quarter of 2024."

07:12 EDT Domino's Pizza names Maureen Pittenger as Chief Human Resources Officer - Domino's Pizza is (DPZ) pleased to announce the appointment of Maureen Pittenger as executive vice president - chief human resources officer, effective July 8. Pittenger will report to Domino's CEO Russell Weiner. In her new role, Pittenger will lead all aspects of Domino's human resources strategies and functions. Pittenger joins Domino's with more than 20 years of experience in human resources. She previously served as senior vice president and chief human resources officer at Dana (DAN), a position she held since 2022.

07:11 EDT AxoGen announces full launch of Avive+ Soft Tissue Matrix - Axogen announces the launch of its newest product, Avive+ Soft Tissue Matrix . Avive+ is intended for use as a soft tissue barrier and is a resorbable, multi-layer amniotic membrane allograft that provides temporary protection and tissue separation during the critical phase of peripheral nerve healing. Avive+ is processed and distributed in accordance with U.S. Food and Drug Administration FDA requirements for Human Cellular and Tissue-based Products or HCT/P, under 21 CFR Part 1271 regulations, U.S. State regulations as a 361 human tissue product. "Product innovation is integral to our mission at Axogen," stated Karen Zaderej, Chairman, CEO, and President. "With the introduction of Avive+ Soft Tissue Matrix, we are excited to enhance our comprehensive solutions for nerve protection and address a significant need for patients with compression or non-transected nerve injuries."

07:10 EDT Trinity Biotech to begin European pre-pivotal trial for CGM sensor - Trinity Biotech announced steps to advance its next generation continuous glucose monitoring solution towards market launch. Since acquiring the CGM technology earlier in the year, Trinity Biotech has been working on further innovations and improvements to the original device. The Company has now received regulatory approval to conduct its initial European pre-pivotal trial that will inform the larger pivotal trial that will be required for product registration and launch. This pre-pivotal trial will begin imminently and is expected to be completed by the end of July. The study will assess the analytical performance of CGM technology enhancements implemented by Trinity Biotech. The data from this analytical performance assessment will be utilised to advance the technical optimization of the next generation CGM device ahead of the pivotal trial that is planned in 2025.

07:09 EDT Oncolytics CEO Matt Coffey, PhD to take a medical leave of absence - Oncolytics Biotech announced that Matt Coffey, PhD, President and CEO of Oncolytics will take a medical leave of absence, effective immediately. Wayne Pisano, Chair of Oncolytics' Board of Directors, will serve as the interim CEO during Dr. Coffey's absence. Wayne Pisano, Chair of the Board since 2013, has more than 30 years of experience as a pharmaceutical industry executive and over 12 years of experience in the biotech industry. Mr. Pisano served as the president of VaxInnate, a privately held biotech company, and has served as a Board Director of several biotech companies, including Provention Bio and Altimmune.

07:08 EDT Ashland appoints Omar Irani as VP, strategy, M&A, portfolio management - Ashland announce that Omar Irani will join the company as vice president strategy, mergers and acquisitions, and portfolio management, effective July 22, 2024. Irani will report to Guillermo Novo, chair and CEO. Previously he held leadership positions with the SI Group, National Refrigerants, Honeywell and ILC Dover in the rubber additives, life sciences and industrial chemicals markets.

07:07 EDT Harmony Biosciences says FDA approves sNDA for WAKIX tablets - Harmony Biosciences announced that the U.S. FDA has approved its supplemental New Drug Application for WAKIX tablets for the treatment of excessive daytime sleepiness in pediatric patients 6 years of age and older with narcolepsy. The FDA separated the submission into two sNDAs for administrative purposes to issue an approval for the treatment of EDS and a complete response for the treatment of cataplexy in pediatric patients with narcolepsy.

07:06 EDT Rani Therapeutics, ProGen partner on development of oral obesity treatment - Rani Therapeutics Holdings has entered into a definitive agreement with ProGen for the co-development and commercialization of RT-114, an oral RaniPill capsule containing ProGen's PG-102, a GLP-1/GLP-2 dual agonist, for the treatment of obesity. Under the terms of the collaboration agreement, Rani and ProGen agree to share responsibilities for the development and commercialization of RT-114 worldwide, including a 50/50 cost and revenue share arrangement. Rani has exclusive rights to lead development and commercialization of RT-114 in the United States, Europe, Canada and Australia, and ProGen has exclusive rights to lead development and commercialization in the rest of the world. Each party has certain rights to sublicense in its territories. Rani is designated to lead operationally in conducting preclinical and development activities through the Phase 1 program, which is expected to initiate in 2025. As part of this agreement, there is no upfront payment or financial exchange between the companies. Rani has developed the RaniPill capsule, which is a novel, proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. Rani has tested 15 molecules in the RaniPill platform. The RaniPill platform has delivered antibodies, peptides and large proteins with high bioavailability. To date, Rani has completed three Phase 1 clinical studies with the RaniPill capsule. Additionally, ProGen's preclinical studies demonstrated that treatment with PG-102 resulted in greater glycemic control while inducing a similar degree of body weight loss versus semaglutide and tirzepatide. ProGen recently presented results from its Phase 1 single-ascending dose study of PG-102, a GLP-1/GLP-2 dual agonist, at the 2024 American Diabetes Association conference in which PG-102 showed a favorable safety profile with lower frequencies of gastrointestinal side effects compared to competitors' trials in similar settings. Additionally, the PK/pharmacodynamic data from this trial and preclinical studies support potential dosing of RT-114 on a weekly to monthly schedule, which could improve patient compliance.

07:06 EDT CytoSorbents announces regulatory approval of CytoSorb in Taiwan - CytoSorbents announces the regulatory approval of CytoSorb in Taiwan by the Taiwan Food and Drug Administration or TFDA The approved indications include the extracorporeal removal of cytokines bilirubi , and myoglobi from a patient's circulating blood. The removal of the antithrombotic drugs Brilinta or ticagrelor, AstraZeneca, and Xarelto during cardiothoracic surgery is also approved, with the goal of reducing perioperative bleeding. CytoSorb will be distributed throughout Taiwan by Hemoscien Corporation. Ms. Bettina Sabisch, Vice President of International Distributor Sales at CytoSorbents stated, "We are thrilled to announce this milestone which underscores the value and efficacy of our CytoSorb therapy and was achieved after navigating a long and complex approval process. We look forward to collaborating with Hemoscien and leveraging their long-standing customer relationships in Taiwan to bring this innovative therapy to patients in need."

07:04 EDT Canoo receives discounted manufacturing assets at Oklahoma facilities - Canoo has received the first of two tranches of new or like-new advanced manufacturing assets, formerly owned by Arrival Automotive UK Limited, at its Foreign Trade Zone designated facility in Oklahoma City, OK. The received assets will bolster in-house processes and enable higher cabin line production volumes in 2025. Canoo received 44 containers with 226 lots of advanced manufacturing assets including state-of-the-art robots along with a suite of comprehensive production infrastructure. These assets will streamline Canoo's production processes, leading to reduced lead times, enhanced production scalability, lower capital expenditures, and eventually lowering unit costs. The Oklahoma City Facility manufactures Canoo's electric cargo vehicles - LDV130 and LDV190.

07:03 EDT Regulus announces 'positive' data from clinical trial of RGLS8429 - Regulus Therapeutics announced positive topline results from the third cohort of patients in its Phase 1b MAD study of RGLS8429 for the treatment of ADPKD. In the third cohort, 16 subjects were randomized 3:1 to receive either 3 mg/kg of RGLS8429 or placebo every other week for three months. RGLS8429 was well tolerated with no safety concerns. Continued evidence of a mechanistic dose response was observed following completion of 3 mg/kg dose level based on urinary PC1 and PC2. 3 mg/kg demonstrated more consistent increases in PC1 and PC2 across patients compared to earlier cohorts Percent change from baseline in PC1 and PC2 demonstrated a dose response across all doses tested, with statistical significance seen at 3 mg/kg compared to placebo. Exploratory MRI imaging analysis suggested RGLS8429 reduced htTKV at 3 mg/kg after 3 months of dosing 70% of subjects demonstrated reductions in htTKV following completion of 3 mg/kg dose level. "We are pleased to see the consistent mechanistic response and reduction in htTKV at the 3mg/kg dose level of RGLS8429 along with an appropriate safety and tolerability profile," said Preston Klassen, M.D., President and Head of Research & Development. "These data support our ongoing and final 300 mg fixed dose cohort in this Phase 1b trial. We believe the data from this study will form the basis for a potentially pivotal Phase 2/3 study of RGLS8429 under an Accelerated Approval regulatory pathway to be discussed with the FDA." "Building on the positive results from our first two cohorts, these cohort 3 data, particularly the reduction in htTKV seen in the majority of patients, further strengthen our conviction in RGLS8429's ability to potentially address the underlying, genetic cause of ADPKD," said Jay Hagan, CEO of Regulus Therapeutics. "We anticipate requesting an End-of-Phase 1 meeting with the FDA in the fourth quarter of this year and look forward to providing a data update from the open-label fourth and final cohort of the Phase 1b MAD study by year-end."

07:03 EDT Progyny announces enhanced global services with acquisition of Apryl - Progyny announced an expansion of its global offering with the acquisition of Apryl, a Berlin-based fertility benefits platform founded in 2019. This acquisition enhances Progyny's guided, concierge support that enables employees around the world to navigate the complexities of fertility and family building care. Progyny's global benefits solution supports multinational employers and their employee populations in over 100 countries. Progyny's services allow employers the flexibility to offer fertility and family building benefits that comply with the intricacies of country-specific laws and regulations as it relates to fertility and family building services, treatments, and benefit design. "Employers recognize the importance of providing fertility and family building benefits and want to be able to streamline these efforts to ensure their employees have equitable benefits and consistent high-touch experiences, regardless of where they live," said Pete Anevski, CEO of Progyny. "We're excited to broaden our support on a global scale."

07:02 EDT GM Financial Bank withdraws application for deposit insurance - General Motors Financial, the finance subsidiary of General Motors, has announced the withdrawal of GM Financial Bank's Interagency Charter and Federal Deposit Insurance Application from further processing by the Federal Deposit Insurance Corporation, FDIC. The application was submitted in late 2020 to both the FDIC and Utah Department of Financial Institution, UDFI. Throughout this more than three-year process, GM Financial Bank has worked constructively and transparently to promptly address all regulatory requests and has developed a strong charter application that satisfies the statutory criteria for approval in the Federal Deposit Insurance Act. The business model is also already in effect for several existing FDIC-insured industrial banks, including other auto manufacturers, but currently excludes American auto manufacturers. On June 14, 2024, the UDFI approved GM Financial Bank's application, appropriately underscoring the strength of the application and the conclusion that General Motors has the financial resources needed to operate an industrial bank in a safe and sound manner and in full compliance with applicable laws and regulations.

07:02 EDT OTC Markets Group welcomes TGS to OTCQX - OTC Markets Group announced TGS ASA, a company that provides energy data and intelligence to companies and investors across energy markets, has qualified to trade on the OTCQX Best Market. TGS ASA upgraded to OTCQX from the Pink market.

06:57 EDT Asensus Surgical: St. Marianna University to lease Senhance Surgical System - Asensus Surgical announced that St. Marianna University School of Medicine Yokohama City Seibu Hospital in Japan has entered into an agreement to lease and utilize a Senhance Surgical System in the Urology and Gastroenterology/General Surgery department.

06:54 EDT Covestro enters 'concrete negotiations' with Adnoc on potential transaction - Covestro stated: "Based on the open-ended talks held so far with Abu Dhabi National Oil Company, or 'Adnoc,' the Board of Management of Covestro AG after consultation with the Supervisory Board has today decided to enter into concrete negotiations with Adnoc regarding a potential transaction and the potential conclusion of an investment agreement as well as to allow for an adequate exchange of company information to confirm assumptions, or confirmatory due diligence. In the view of the Board of Management, the discussions so far have shown that Covestro and Adnoc can generally reach a common understanding regarding core aspects of a possible transaction including support for Covestro's further growth strategy. Starting point for the negotiations is a possible offer price of EUR 62 per Covestro share that Adnoc has indicated to Covestro, which is subject, among other things, to the results of the confirmatory due diligence and agreement on the content of an investment agreement." Reference Link

06:48 EDT International Game announces release of Whitney Houston Slots game - International Game Technology has released the highly anticipated Whitney Houston Slots game, giving players across the U.S. an exciting new entertainment opportunity at their favorite casinos. The dazzling game is bringing the "Voice of a Generation" to a growing list of casinos, delivering an immersive experience that is sure to captivate Whitney Houston fans and slot enthusiasts alike.

06:48 EDT MGM Resorts unit to acquire Tipico's U.S. sportsbook - MGM Resorts International announced that its subsidiary, LeoVegas Group, has entered into an agreement to acquire the product and technology platform constituting the U.S sportsbook and online casino from Tipico Group Ltd. This acquisition is the second major investment by LeoVegas, following the acquisition of game developer Push Gaming in 2023. The acquisition will allow LeoVegas to operate a purpose-built proprietary sportsbook across all international markets and brands, with the exception of those exclusive to the BetMGM JV, with a focus on a clean, fast consumer experience with top-class product, pricing and functionality. Tipico will wind down its U.S. operations prior to the closing of the acquisition. As part of the transaction, LeoVegas will acquire certain of Tipico's U.S. facing management, technology and trading teams across the U.S., Colombia and Europe. The transaction is subject to customary closing conditions and is expected to be completed in the third quarter of 2024.

06:46 EDT BioNTech, DualityBio receive FDA Fast Track designation for BNT324/DB-1311 - BioNTech and Duality Biologics announced that the U.S. FDA granted Fast Track designation for BNT324/DB-1311 for the treatment of patients with advanced/unresectable, or metastatic castration-resistant prostate cancer who have progressed on or after standard systemic regimens. BNT324/DB-1311 is a next-generation antibody-drug conjugate candidate targeting the transmembrane glycoprotein B7-H3, an immune checkpoint protein which is overexpressed in a range of tumor types and has been associated with disease progression and poor prognosis for patients. The candidate is currently being evaluated in an ongoing Phase 1/2 study in patients with advanced solid tumors.

06:34 EDT G1 Therapeutics backs FY24 COSELA net revenue view $60M-$70M - G1 reaffirmed its full year 2024 COSELA net revenue guidance and updated its cash runway guidance. G1's guidance is based on current expectations for continued sales growth of COSELA in the U.S. and achievement of its forecasts. The company expects to generate between $60M-$70M in COSELA net revenue in 2024. Additionally, G1 plans to wind down the Phase 3 PRESERVE 2 trial, discontinue the anticipated hiring of staff and investment for a 1L TNBC indication and make targeted headcount reductions outside of the existing commercial organization to streamline the company. These efforts are expected to provide sufficient cash runway to achieve anticipated company profitability in the second half of 2025.

06:32 EDT NexGen advances through completeness check for environmental assessment process - NexGen Energy announced that on June 21, 2024 the Canadian Nuclear Safety Commission concluded their 30-day completeness check of NexGen's May 21, 2024 submission of responses to the remaining 49 technical review comments and revised Federal Environmental Impact Statement (for NexGen's 100% owned Rook I Project. The technical review by the CNSC has now commenced through the Federal-Indigenous Review Team, and upon confirmation that all technical review comments have been resolved after its prescribed 60-day review, the CNSC will then be able to deem the EIS final. When the EIS is deemed final, the CNSC will establish the Federal Commission Hearing date.

06:21 EDT GSK reports EMA accepts Jemperli plus chemo application for review - GSK plc announced the European Medicines Agency has accepted its application to expand the use of Jemperli in combination with standard-of-care chemotherapy to all adult patients with primary advanced or recurrent endometrial cancer. The EMA's Committee for Medicinal Products for Human Use will begin the formal review process to make a recommendation to the European Commission, with approval expected in the first half of 2025. Currently, in the EU, Jemperli in combination with carboplatin and paclitaxel is approved for the treatment of adult patients who are candidates for systemic therapy with primary advanced or recurrent endometrial cancer that is mismatch repair deficient, or dMMR, or microsatellite instability-high (MSI-H). If this new application is approved, dostarlimab would be expanded to all patients with primary advanced or recurrent endometrial cancer, regardless of their biomarker type, including those with mismatch repair proficient/microsatellite stable tumours where currently there are no approved frontline immuno-therapy-based treatments in the EU.

06:14 EDT Arthur J. Gallagher acquires ICSR, terms not disclosed - Arthur J. Gallagher & Co. announced that its captive and alternative risk transfer solutions subsidiary, Artex, has acquired London-based Implement Compliance Solutions & Resources Limited. Terms of the transaction were not disclosed.

06:10 EDT Comstock Mining unit receives CUP from Lyon County, Nevada - Comstock announced that its subsidiary, Comstock Metals, received unanimous approval for a conditional use permit from the Lyon County, Nevada, Board of County Commissioners, for the operations and material storage of solar panels at the company's first planned industrial-scale facility in Silver Springs, Nevada. This permit marks an earlier than expected achievement for deploying the first industry-scale solar panel recycling facility in the region.

06:09 EDT Entrada Therapeutics reports 'positive' data from Phase 1 ENTR-601-44-101 trial - Entrada Therapeutics announced positive preliminary data from its Phase 1 clinical trial, ENTR-601-44-101. Data will be featured in a presentation at the 29th Annual Congress of the World Muscle Society, taking place in Prague, Czechia from October 8-12, 2024. "We are excited to present the first clinical data from our Duchenne franchise, led by ENTR-601-44. ENTR-601-44 was well tolerated in healthy volunteers and we are pleased to see significant plasma concentration, muscle concentration and exon skipping. We achieved the goals of the ENTR-601-44-101 trial, including the identification of a clinically relevant starting dose for the planned Phase 2 global patient study. Based on the cumulative data to date, we expect to see a significant accumulation of exon skipping and dystrophin production in patients, which we believe will lead to an improvement in functional outcomes after multiple doses," said Dipal Doshi, Chief Executive Officer at Entrada Therapeutics. There were no serious adverse events, no drug-related adverse events and no clinically significant changes or trends noted in vital signs, ECGs, physical exams or laboratory assessments observed in the trial. The study demonstrated target engagement as measured by exon skipping on a ng/g of tissue adjusted basis supporting the importance of endosomal escape to therapeutic index optimization. Muscle concentration was detected in all six subjects in the 6 mg/kg dose cohort and mean target engagement as measured by exon skipping was 0.44%. Exon skipping was statistically significant compared to the placebo control in the 6 mg/kg dose cohort. These results are based upon data collected to date and are aggregated based upon the placebo and study drug groups. Based on the positive preliminary data from the Phase 1 clinical trial, the Company is on track to submit regulatory applications in the fourth quarter of 2024 to initiate separate global Phase 2 clinical trials for ENTR-601-44 in patients with Duchenne who are exon 44 skipping amenable and for ENTR-601-45 in patients with Duchenne who are exon 45 skipping amenable. In addition, the company plans to submit regulatory applications in 2025 to initiate a global Phase 2 clinical trial for its third Duchenne candidate, ENTR-601-50, in patients who are exon 50 skipping amenable.

06:06 EDT Group 1 Automotive says CDK cybersecurity incident disrupts business processes - Group 1 Automotive announced that the cybersecurity incident recently experienced by third-party software provider, CDK Global, has disrupted Group 1's business applications and processes in its U.S. operations that rely on CDK's dealers' systems. In response, the Company immediately activated its cyber incident response procedures and proactively took measures to protect and isolate its systems from CDK's platform. Despite the CDK service outage, all Group 1 U.S. dealerships continue to conduct business using alternative processes until CDK's dealers' systems are available. The Company's dealerships in the U.K. do not use CDK's dealers' systems and are therefore not impacted by the CDK service outage. CDK has advised that it anticipates the restoration of the dealer management system will require several days and not weeks. The timing of the restoration of other impacted CDK applications remains unclear at this time. Group 1's ability to determine the material impact, if any, of the CDK incident and the resulting service outage, will ultimately depend on a number of factors, including when, and to what extent, the Company resumes its access to CDK's dealers' systems. Group 1 is closely monitoring this situation and will take additional action if determined necessary.

06:03 EDT Advanced Energy to acquire Airity Technologies, terms not disclosed - Advanced Energy Industries announced the acquisition of Airity Technologies, a Redwood City, California-based provider of next-generation, high voltage power conversion products and technologies for applications in semiconductor, industrial and medical markets. The company expects the acquisition to be immaterial to 2024 financial forecasts. Terms were not disclosed.

06:02 EDT Sonoco Products to acquire Eviosys for $3.9B - Sonoco Products announced it has entered into an agreement to acquire Eviosys, Europe's leading food cans, ends and closures manufacturer, from KPS Capital Partners for approximately $3.9B. Eviosys has the largest metal food can manufacturing footprint in the EMEA region, with approximately 6,300 employees in 44 manufacturing facilities across 17 countries. Sonoco estimates Eviosys's 2024 revenues will be approximately $2.5 billion and its 2024 adjusted EBITDA will be approximately $430 million. Eviosys has meaningful commercial and operational momentum and has increased EBITDA by approximately 50% since 2021. Sonoco expects to achieve over $100 million of synergies from the integration of Eviosys with Sonoco's complementary metal can business. Rodger Fuller, Sonoco's Chief Operating Officer, will lead the integration with a focus on customer and supplier relationships, employee continuity, operational excellence, and synergy realization, while combining the best of Sonoco's culture with the rich history and heritage of Eviosys. Under the terms of the agreement, Sonoco will acquire Eviosys from KPS for approximately $3.9 billion on a cash-free, debt-free basis. Sonoco has committed financing for the entirety of the transaction price. The Boards of Directors of both companies have unanimously approved the transaction. The Transaction expected to occur by the end of 2024, subject to the completion of required works council consultations, the receipt of required regulatory approvals and other customary closing conditions. Eviosys's current CEO, Tomas Lopez, will remain with Sonoco and lead the company's EMEA metal packaging business.

06:00 EDT Sonoco Products to acquire Eviosys for $3.9B

05:57 EDT Sophia Genetics launches new Residual Acute Myeloid Application - Sophia Genetics announced its new Residual Acute Myeloid Application. The new offering expands the company's comprehensive oncology portfolio to support measurable residual disease capabilities and will be available to customers worldwide this summer.

05:34 EDT Sen. Blackburn: 'To Meta, our kids are the product,' calls for passing of KOSA - Tennessee Senator Marsha Blackburn said via X, the platform formerly called Twitter, on Saturday: "One of Meta's executives warned in 2019 of the addictive impacts Instagram and Facebook have on teens. Yet, when he asked CEO Mark Zuckerberg for funding to fix these problems, his request was denied. To Meta, our kids are the product. This is why we need to pass KOSA." Reference Link